<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        1506233816
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2004
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        LEVITRA 5MG TABLET
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        VARDENAFIL
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        5
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        mg
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Oral use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Film-coated tablet
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        4
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Blister
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        NCE
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        36
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store below 25°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        48.30
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="BAYER AG" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            BAYER AG
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 2947]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            Bayer Saudi Arabia
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            BAYER AG
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        G04BE09
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Levitra contains vardenafil, a member of a class of medicines called phosphodiesterase<br />type 5 inhibitors. They are used for the treatment of erectile dysfunction in adult men, a<br />condition which implies difficulties in getting or keeping an erection.<br />At least one in ten men has trouble getting or keeping an erection at some time. There may<br />be physical or psychological causes, or a mixture of both. Whatever the cause is, due to<br />muscle and blood vessel changes not enough blood stays in the penis to make it hard and<br />keep it hard.<br />Levitra will only work when you are sexually stimulated. It reduces the action of the<br />natural chemical in your body which makes erections go away. Levitra allows an erection<br />to last long enough for you to satisfactorily complete sexual activity.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Do not take Levitra</strong><br /><strong>▸</strong> If you are allergic to vardenafil or any of the other ingredients of this medicine (listed in<br />section 6). Signs of an allergic reaction include a rash, itching, swollen face or lips and<br />shortness of breath.</p><p><strong>▸</strong> If you are taking medicines containing nitrates, such as glycerol trinitrate for angina,<br />or nitric oxide donors, such as amyl nitrite. Taking these medicines with Levitra could<br />seriously affect your blood pressure.<br /><strong>▸</strong> If you are taking ritonavir or indinavir, medicines used to treat human<br />immunodeficiency virus (HIV) infections.<br /><strong>▸</strong> If you are over 75 years of age and are taking ketoconazole or itraconazole, anti-fungal<br />medicines.<br /><strong>▸</strong> If you have a severe heart or liver problem.<br /><strong>▸</strong> If you are having kidney dialysis.<br /><strong>▸</strong> If you have recently had a stroke or heart attack.<br /><strong>▸</strong> If you have or have had low blood pressure.<br /><strong>▸</strong> If your family has a history of degenerative eye diseases (such as retinitis pigmentosa).<br /><strong>▸</strong> If you have ever had a condition involving loss of vision due to damage to the optic<br />nerve from insufficient blood supply known as non-arteritic ischemic optic neuropathy<br />(NAION).<br /><strong>▸</strong> If you are taking riociguat. This drug is used to treat pulmonary arterial hypertension<br />(i.e., high blood pressure in the lungs) and chronic thromboembolic pulmonary<br />hypertension (i.e., high blood pressure in the lungs secondary to blood clots). PDE5<br />inhibitors, such as Levitra have been shown to increase the hypotensive effects of this<br />medicine. If you are taking riociguat or are unsure tell your doctor.<br /><strong>Warnings and precautions</strong><br />Talk to your doctor or pharmacist before taking Levitra.<br />Take special care with Levitra<br /><strong>▸</strong> If you have heart trouble. It may be risky for you to have sex.<br /><strong>▸</strong> If you suffer from irregular heart beat (cardiac arrhythmia) or inherited heart diseases<br />affecting your electrocardiogram.<br /><strong>▸</strong> If you have a physical condition affecting the shape of the penis. This includes<br />conditions called angulation, Peyronie&rsquo;s disease and cavernosal fibrosis.</p><p><strong>▸</strong> If you have an illness that can cause erections which won&rsquo;t go away (priapism). These<br />include sickle cell disease, multiple myeloma and leukaemia.<br /><strong>▸</strong> If you have stomach ulcers (also called gastric or peptic ulcers).<br /><strong>▸</strong> If you have a bleeding disorder (such as haemophilia).<br /><strong>▸</strong> If you are using any other treatments for erection difficulties, including Levitra<br />orodispersible tablets (see section: Other medicines and Levitra).<br /><strong>▸</strong> If you experience sudden decrease or loss of vision, stop taking Levitra and contact your<br />doctor immediately.<br /><strong>Children and adolescents</strong><br />Levitra is not intended for use by children or adolescents under 18.<br /><strong>Other medicines and Levitra</strong><br />Please tell your doctor or pharmacist if you are using, have recently used or might use any<br />other medicines, including medicines obtained without a prescription.<br />Some medicines may cause problems, especially these:<br /><strong>▸</strong>Nitrates, medicines for angina, or nitric oxide donors, such as amyl nitrite. Taking these<br />medicines with Levitra could seriously affect your blood pressure.<br /><strong>▸</strong> Medicine for the treatment of arrhythmias, such as quinidine, procainamide,<br />amiodarone or sotalol.<br /><strong>▸</strong> Ritonavir or indinavir, medicines for HIV.<br /><strong>▸</strong> Ketoconazole or itraconazole, anti-fungal medicines.<br /><strong>▸</strong> Erythromycin, or clarithromycin, macrolide antibiotics.<br /><strong>▸</strong> Alpha-blockers, a type of medicine used to treat high blood pressure and enlargement<br />of the prostate (as benign prostatic hyperplasia).<br /><strong>▸</strong> Riociguat.<br />Do not use Levitra film-coated tablets combined with any other treatment for erectile<br />dysfunction, including Levitra orodispersible tablets.<br /><strong>Levitra with food, drink and alcohol</strong><br /><strong>▸</strong> You can take Levitra with or without food &ndash; but preferably not after a heavy or high-fat<br />meal as this may delay the effect.<br /><strong>▸</strong> Don&rsquo;t drink grapefruit juice when you use Levitra. It can interfere with the usual effect<br />of the medicine.<br /><strong>▸</strong> Alcoholic drink can make erection difficulties worse.<br /><strong>Pregnancy and breast-feeding</strong><br />Levitra is not for use by women.<br /><strong>Driving and using machines</strong><br />Levitra might make some people feel dizzy or affect their vision. If you feel dizzy, or if your<br />vision is affected after taking Levitra don&rsquo;t drive or operate any tools or machines.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Always take this medicine exactly as your doctor has told you. Check with your doctor or<br />pharmacist if you are not sure. The recommended dose is 10 mg.<br />Take a Levitra tablet about 25 to 60 minutes before sexual activity. With sexual stimulation<br />you may achieve an erection anywhere from 25 minutes up to four to five hours after<br />taking Levitra.<br /><strong>▸</strong> Swallow one tablet with a glass of water<br /><strong>Do not take Levitra film-coated tablets with any other forms of Levitra.<br />Do not take Levitra</strong> more than once a day.<br />Tell your doctor if you think Levitra is too strong or too weak. He or she may suggest a<br />switch to an alternative Levitra formulation with a different dose, depending on how well it<br />works for you.<br /><strong>If you take more Levitra than you should</strong><br />Men who take too much Levitra may experience more side effects or may get severe back<br />pain. If you take more Levitra than you should, tell your doctor.<br />If you have any further questions on the use of this medicine, ask your doctor or<br />pharmacist.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, this medicine can cause side effects, although not everybody gets them.<br />Most of the effects are mild or moderate.<br />Partial, sudden, temporary or permanent decrease or loss of vision in one or both eyes has<br />been experienced by patients. Stop taking Levitra and contact your doctor immediately.<br />Sudden decrease or loss of hearing has been reported.<br />Cases of sudden death, fast or altered heart beat, heart attack, chest pain, and trouble in<br />cerebral circulation (including temporarily decreased blood flow to parts of the brain and<br />bleeding in the brain) have been reported in men taking vardenafil. Most of the men who<br />experienced these side effects had heart problems before taking this medicine. It is not<br />possible to determine whether these events were directly related to vardenafil.<br />The chance of having a side effect is described by the following categories:<br /><strong>Very common:</strong> (may affect more than 1 in 10 users)<br /><strong>▸</strong> Headache<br /><strong>Common: </strong>(may affect up to 1 in 10 users)<br /><strong>▸</strong> Dizziness</p><p><strong>▸</strong> Flushing<br /><strong>▸</strong> Blocked or runny nose<br /><strong>▸</strong> Indigestion<br />Uncommon: (may affect up to 1 in 100 users)<br /><strong>▸</strong> Swelling of skin and mucous tissue including swollen face, lips or throat<br /><strong>▸</strong>Sleep disorder<br /><strong>▸</strong> Numbness and impaired perception of touch<br /><strong>▸</strong> Sleepiness<br /><strong>▸</strong> Effects on vision; redness of the eye, effects on colour vision, eye pain and discomfort,<br />light sensitivity<br /><strong>▸</strong> Ringing in the ears; vertigo<br /><strong>▸</strong> Fast heart beat or pounding heart<br /><strong>▸</strong> Breathlessness<br /><strong>▸</strong>Stuffy nose<br /><strong>▸</strong> Acid reflux, gastritis, abdominal pain, diarrhoea, vomiting; feeling sick (nausea), dry<br />mouth<br /><strong>▸</strong> Raised levels of liver enzymes in your blood<br /><strong>▸</strong> Rash, reddened skin<br /><strong>▸</strong> Back or muscle pain; increase in blood of a muscle enzyme (creatine phosphokinase),<br />muscle stiffness<br /><strong>▸</strong> Prolonged erections<br /><strong>▸</strong> Malaise<br />Rare: (may affect up to 1 in 1,000 users)<br /><strong>▸</strong> Inflammation of the eyes (conjunctivitis)<br /><strong>▸</strong> Allergic reaction<br /><strong>▸</strong> Anxiety<br /><strong>▸</strong> Fainting<br /><strong>▸</strong> Amnesia<br /><strong>▸</strong> Seizure<br /><strong>▸</strong> Increased pressure in the eye (glaucoma), lacrimation increased<br /><strong>▸</strong>Effects on the heart (such as heart attack, altered heart beat or angina)<br /><strong>▸</strong> High or low blood pressure<br /><strong>▸</strong>Nose bleed<br /><strong>▸</strong> Effect on results of blood tests to check liver function<br /><strong>▸</strong> Sensitivity of the skin to sun light<br /><strong>▸</strong> Painful erections<br /><strong>▸</strong> Chest pain<br /><strong>▸</strong> Temporarily decreased blood flow to parts of the brain<br />Very rare or not known: (may affect less than 1 in 10,000 users or frequency cannot be<br />estimated from the available data)<br /><strong>▸</strong> Blood in the urine (Haematuria)<br /><strong>▸</strong> Penile bleeding (Penile Haemorrhage)<br /><strong>▸</strong> Presence of blood in the semen (Haematospermia)<br /><strong>▸</strong> Sudden death<br /><strong>▸</strong> Bleeding in the brain<br />Reporting of side effects<br />If you get any side effects, talk to your doctor. This includes any possible side effects not<br />listed in this leaflet. By reporting side effects, you can help provide more information on<br />the safety of this medicine.</p><table cellspacing="0" cellpadding="0" border="1"><tbody><tr><td colspan="2" style="height:17.45pt; vertical-align:top; width:391.3pt"><p style="text-align:center"><strong>To report any side effect(s):</strong></p></td></tr><tr><td style="height:17.45pt; vertical-align:top; width:195.65pt"><p><strong>Saudi Arabia</strong></p><p>The National Pharmacovigilance Centre</p><p>(NPC).</p><p>Fax: + 966 - 11 - 205 - 7662.</p><p>SFDA call center: 19999.</p><p>Email: npc.drug@sfda.gov.sa</p><p>Website: https://ade.sfda.gov.sa</p></td><td style="height:17.45pt; vertical-align:top; width:195.65pt"><p><strong>Jordan:</strong></p><p>Tel: +962 - 65632000 / +962 - 64602550</p><p>Fax: +962 - 65105916 / +962 - 65105893</p><p>Email: info@jfda.jo</p><p>Website: www.jfda.jo</p></td></tr><tr><td style="height:17.45pt; vertical-align:top; width:195.65pt"><p><strong>Iraq:</strong></p><p>Email: iraqiphvc@moh.gov.iq</p><p>Email: iqphvc@yahoo.com</p><p>Website: www.moh.gov.iq</p></td><td style="height:17.45pt; vertical-align:top; width:195.65pt"><p><strong>Lebanon:</strong></p><p>Website: www.moph.gov.lb</p></td></tr><tr><td style="height:17.45pt; vertical-align:top; width:195.65pt"><p><strong>Egypt:</strong></p><p>Egyptian Pharmaceutical Vigilance</p><p>Centre</p><p>Tel.: +20 -225354100 Ext.:1303</p><p>Email: pv.center@eda.mohealth.gov.eg</p></td><td style="height:17.45pt; vertical-align:top; width:195.65pt"><p><strong>United Arab Emirates (UAE):</strong></p><p>Tel: 80011111 / +971 42301000</p><p>Email: pv@moh.gov.ae</p><p>Website: www.moh.gov.ae</p><p>P.O.Box 1853 Dubai</p></td></tr><tr><td style="height:17.45pt; vertical-align:top; width:195.65pt"><p><strong>Kuwait:</strong></p><p>Hotline: 1810005</p><p>Email: health@moh.gov.kw</p><p>Website: www.moh.gov.kw/kdfc/</p><p>P.O.Box: 5 Safat, 13001 Kuwait</p></td><td style="height:17.45pt; vertical-align:top; width:195.65pt"><p><strong>Oman:</strong></p><p>Tel: +968 - 2444 1999</p><p>Fax: +968 - 24602287</p><p>Email: dg-padc@moh.gov.om</p><p>Website: www.moh.gov.om</p></td></tr><tr><td style="height:17.45pt; vertical-align:top; width:195.65pt"><p><strong>Qatar:</strong></p><p>Website: moph.gov.qa</p></td><td rowspan="2" style="height:17.45pt; vertical-align:top; width:195.65pt"><p><strong>Sudan:</strong></p><p>National Medicines and Poisons Board (NMPB)</p><p>Fax: +249 - 183522263</p><p>Email: info@nmpb.gov.sd</p><p>Website: www.nmpb.gov.sd</p></td></tr><tr><td style="height:17.45pt; vertical-align:top; width:195.65pt"><p><strong>Bahrain:</strong></p><p>Website: moh.gov.bh</p></td></tr><tr><td style="height:17.45pt; vertical-align:top; width:195.65pt"><p><strong>Yemen:</strong></p><p>Tel: +967 - 1836060</p><p>Fax: +967 -1619170</p><p>Email: sbdma@y.net.ye</p><p>Website: www.sbd-ye.org</p></td><td style="height:17.45pt; vertical-align:top; width:195.65pt"><p><strong>Libya:</strong></p><p>Tel: +218 -214631353 /+218 -214631342</p><p>Fax: +218 -214631334</p><p>Email: info@health.gov.ly</p><p>Website: www.health.gov.ly</p></td></tr></tbody></table><p>&nbsp;</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Keep this medicine out of the sight and reach of children.<br />Do not use this medicine after the expiry date which is stated on the carton after &ldquo;EXP&rdquo;. The<br />expiry date refers to the last day of that month.<br />Do not store above 25&deg;C. Keep in dry place.<br />Do not throw away any medicines via wastewater or household waste. Ask your pharmacist<br />how to throw away medicines you no longer use. These measures will help protect the<br />environment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>▸</strong> The active substance is vardenafil. Each tablet contains 5 mg of vardenafil (as<br />hydrochloride).<br /><strong>▸</strong> The other ingredients of the tablets are:<br />Tablet core: crospovidone, magnesium stearate, microcrystalline cellulose, colloidal<br />anhydrous silica.<br />Film coat: macrogol 400, hypromellose, titanium dioxide (E171), ferric oxide<br />yellow (E172), ferric oxide red (E172).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                Levitra 5 mg film-coated tablets are orange with the BAYER cross on one side and the
strength (5) on the other side. The tablets are provided in blister packs containing 2, 4, 8,
12 or 20 tablets.
Not all pack sizes may be marketed.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Manufacturer Marketing<br />Authorisation Holder:</strong><br />Bayer AG.<br />51368 Leverkusen,<br />Germany.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                March 2020
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p dir="RTL" style="text-align:right">يحتوي ليفيترا على فاردينافيل، الذي ينتمي لمجموعة الأدوية التي تسمى مثبطات النوع 5 من (إنزيم) فسفودايستراز. تستخدم لعلاج الاختلال الوظيفي الانتصابي في الرجال البالغين، هي حالة تتضمن صعوبات حدوث أو ابقاء وضع الانتصاب.</p><p dir="RTL" style="text-align:right">على الأقل واحد من كل عشرة رجال لديه مشكلة في حدوث أو إبقاء الانتصاب في بعض الأوقات. ربما يكون ذلك لأسباب جسدية أو نفسية، أو مزيجا من الاثنين معاً. مهما يكن السبب، فأن بقاء الدم بكمية غير كافية في القضيب (العضو الذكري) لانتصابه و لإبقائه منتصباً ناجما عن تغيرات في العضلة و الوعاء الدموي.</p><p dir="RTL" style="text-align:right">سوف يعمل ليفيترا فقط عندما تحدث لك إثارة جنسية. إنه يقلل فاعلية المادة الكيميائية الطبيعية في جسمك التي تجعل الانتصاب يَضْعُف و ينقضي. يسمح ليفيترا للانتصاب أن يدوم لمدة كافية للقيام بنشاط جنسي كامل عَلَى نَحْوٍ مُرْض.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL" style="text-align:right"><strong>لا تتناول ليفيترا</strong></p><p dir="RTL" style="text-align:right">إذا كان لديك حساسية للفاردينافيل أو لأي من المكونات الأخرى في الليفيترا (المذكورة في الجزء 6). تشمل علامات تفاعل الحساسية على طفح جلدي، حكة جلدية، تورم الوجه أو الشفتين و قصور في التنفس.</p><p dir="RTL" style="text-align:right">إذا كنت تتناول أدوية تحتوي على نِّترات، مثل جليسيرول ثُلاَثِيُّ النَّتْرات لعلاج الذَبْحَة، أو مانحات أكسيد النتريك مثل اميل النتريت. إن تناول هذه الأدوية مع ليفيترا يمكن أن يؤثر بصورة خطيرة على ضغط الدم.</p><p dir="RTL" style="text-align:right">إذا كنت تتناول الريتونافير أو الإندينافير، أدوية تستخدم لعلاج عدوى فيروس نقص المناعة في الانسان (HIV).</p><p dir="RTL" style="text-align:right">إذا كان السن أكثر من 75 عاماً و تتناول الكيتوكونازول أو الايتراكونازول، أدوية مضادة للفطريات.</p><p dir="RTL" style="text-align:right">إذا كنت تعاني من مشكلة شديدة في القلب أو الكبد.</p><p dir="RTL" style="text-align:right">إذا كان يجرى لك غسيل كلوي</p><p dir="RTL" style="text-align:right">إذا كنت قد عانيت حديثاً من سكتة دماغية أو نوبة قلبية</p><p dir="RTL" style="text-align:right">إذا كنت تعاني أو عانيت من انخفاض في ضغط الدم</p><p dir="RTL" style="text-align:right">إذا كانت اسرتك لديها سَوَابِق مرضية في أمراض العين الانحلالية-الانتكاسية (مثل الْتِهابُ الشبكية الاصطباغي - عشى ليلي).</p><p dir="RTL" style="text-align:right">إذا كنت قد عانيت في أي وقت مضى من حالة تشتمل على فقدان البصر نتيجة تَلَف في العصب البصري ناتج عن نقص الإمداد الدموي المعروف باعتلال عصبي بصري إقفاري غير شِّرْيَاني (NAION).</p><p dir="RTL" style="text-align:right">إذا كنت تأخذ ريوسيجوات. يستخدم هذا الدواء لعلاج ارتفاع ضغط الدم الشرياني الرئوي (أي ارتفاع ضغط الدم في الرئتين) وارتفاع ضغط الدم الرئوي المزمن للانسداد التجلطي (أي ارتفاع ضغط الدم في الرئتين الثانوية لتجلط الدم). وقد أظهرت مثبطات PDE5، مثل ليفيترا زيادة التأثير الخافض للضغط من هذا الدواء. إذا كنت تأخذ ريوسيجوات أو غير متأكد أخبر طبيبك</p><p dir="RTL" style="text-align:right"><strong>التحذيرات و الاحتياطات</strong></p><p dir="RTL" style="text-align:right">أبلغ طبيبك أو الصيدلي قبل تناول ليفيترا.</p><p dir="RTL" style="text-align:right"><strong>اتخذ عناية خاصة مع ليفيترا</strong></p><p dir="RTL" style="text-align:right">إذا كنت تعاني من اضطرابات قلبية. ربما يعرضك ممارسة الجنس للخطورة.</p><p dir="RTL" style="text-align:right">إذا كنت تعاني من عدم انتظام ضَرْبَات القلب (اضطراب النظم القلبية) أو أي أمراض مُتَوَارَثة للقلب تؤثر على الرسم الكهربائي للقلب.</p><p dir="RTL" style="text-align:right">إذا كان لديك حالة جسدية تؤثر على شكل القضيب (العضو الذكري). تشمل هذه لحالات تسمى بالتَزَوِّي، مرض البايروني و التليف التجويفي</p><p dir="RTL" style="text-align:right">إذا كنت تعاني من مرض يمكن أن يسبب حالة انتصاب مستمر (القُسَاح) بقاء الإنعاظ. يتضمن ذلك داءُ الكرَيَّاتِ المنجلية و ورم نِقْيِيّ المتعدد و ابيضاض الدم (الليوكيميا).</p><p dir="RTL" style="text-align:right">إذا كنت تعاني من قرحات في المعدة (تسمى أيضاً قرحات معدية أو قرحات هضمية).</p><p dir="RTL" style="text-align:right">إذا كنت تعاني من اضطراب نزفي (مثل الهيموفيليا).</p><p dir="RTL" style="text-align:right">إذا كنت تتناول أي علاجات أخرى لصعوبة الانتصاب، يشمل ذلك أقراص ليفيترا القابلة للذوبان في الفم (أنظر الجزء: أدوية أخرى و ليفيترا).</p><p dir="RTL" style="text-align:right">إذا عانيت من نقص مفاجئ أو فقدان في حاسة البصر، توقف عن تناول ليفيترا و اتصل فوراً بالطبيب.</p><p dir="RTL" style="text-align:right"><strong>الأطفال و المراهقين</strong></p><p dir="RTL" style="text-align:right">لا يعطى للأطفال أو المراهقين تحت سن الـ 18.</p><p dir="RTL" style="text-align:right"><strong>أدوية اخرى و ليفيترا</strong></p><p dir="RTL" style="text-align:right">الرجاء ابلاغ طبيبك أو الصيدلي إذا كنت تتناول أو تناولت حديثاً أو يمكن أن تتناول أية أدوية أخرى، تشمل الأدوية التي يتم الحصول عليها بدون وصفة طبية.</p><p dir="RTL" style="text-align:right">يمكن أن تسبب بعض الأدوية مشاكل، خاصة الآتية:</p><p dir="RTL" style="text-align:right">النترات، أدوية علاج الذَبْحَة، أو مانحات أكسيد النترات، مثل اميل نتريت. تناول تلك الأدوية مع ليفيترا يمكن أن يؤثر بشكل خطير على ضغط الدم.</p><p dir="RTL" style="text-align:right">أدوية لعلاج عدم انتظام نبض القلب، مثل الكوينيدين، بروكاييناميد، أميودارون أو سوتالول</p><p dir="RTL" style="text-align:right">ريتونافير أو إندينافير، أدوية لعلاج فيروس نقص المناعة في الانسان (HIV).</p><p dir="RTL" style="text-align:right">كيتوكونازول أو ايتراكونازول، أدوية مضادة للفطريات.</p><p dir="RTL" style="text-align:right">اريثرومايسين، أو كلاريثرومايسين، مضادات حيوية من مجموعة الماكروليد.</p><p dir="RTL" style="text-align:right">محصرات - الألفا، نوع من الأدوية تستخدم لعلاج ضغط الدم المرتفع و تضخم البروستات (فرط التنسج الحميد للبروستات).</p><p dir="RTL" style="text-align:right">ريوسيجوات.</p><p dir="RTL" style="text-align:right">لا تتناول ليفيترا أقراص ذات كسوة غشائية في نفس الوقت مع أي علاج آخر لصعوبة الانتصاب، يشمل أقراص ليفيترا القابلة للذوبان في الفم</p><p dir="RTL" style="text-align:right"><strong>ليفيترا مع الأطعمة، المشروبات و الكحوليات</strong></p><p dir="RTL" style="text-align:right">يمكنك تناول ليفيترا سواء مع أو بدون طعام، لكن يفضل عدم تناوله بعد وجبة دسمة أو ذات نسبة دهون عالية لأن ذلك قد يؤجل مفعول الدواء.</p><p dir="RTL" style="text-align:right">لا تشرب عصير الجريب فروت عندما تتناول الليفيترا. من الممكن أن يتعارض ذلك مع التأثير المعتاد للدواء.</p><p dir="RTL" style="text-align:right">إن شرب المشروبات الكحولية يجعل صعوبات الانتصاب أسوأ.</p><p dir="RTL" style="text-align:right"><strong>الحمل و الرضاعة:&nbsp; </strong></p><p dir="RTL" style="text-align:right">ليفيترا لا يستخدم في النساء.</p><p dir="RTL" style="text-align:right"><strong>القيادة و استخدام الآلات:</strong></p><p dir="RTL" style="text-align:right">قد يشعر بعض الأفراد بالدوار أو تتأثر قدرتهم على الرؤية مع استخدام ليفيترا. إذا شعرت بدوار، أو إذا تأثرت الرؤية لديك بعد تناول ليفيترا لا تقوم بالقيادة أو تشغيل المعدات أو الآلات.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL" style="text-align:right">تناول دائماً هذا الدواء بدقة كما يوصي به طبيبك. راجع طبيبك أو الصيدلي إذا كنت غير متأكداً. الجرعة الموصي بها هي 10 ميليغرام.</p><p dir="RTL" style="text-align:right">تناول قرص ليفيترا قبل مزاولة النشاط الجنسي بفترة من 25 إلى 60 دقيقة تقريباً. مع الإثارة الجنسية يمكنك تحقيق انتصاب في أي فترة ما بين 25 دقيقة حتى أربع أو خمس ساعات بعد تناول ليفيترا.</p><p dir="RTL" style="text-align:right">ابلع قرص ليفيترا مع كوب من الماء.</p><p dir="RTL" style="text-align:right"><strong>لا تتناول أقراص ليفيترا ذات كسوة غشائية</strong> مع أي أشكال أخرى من ليفيترا.</p><p dir="RTL" style="text-align:right"><strong>لا تتناول ليفيترا</strong> أكثر من مرة واحدة يومياً.</p><p dir="RTL" style="text-align:right">قم بإبلاغ طبيبك إذا كنت تعتقد بأن فاعلية ليفيترا قوية جداً أو ضعيفة جداً. فربما يقترح الطبيب التحول لتركيبة بديلة بجرعة مختلفة، تعتمد على كيفية تأثير الليفيترا عليك.</p><p dir="RTL" style="text-align:right"><strong>إذا تناولت جرعة أكبر من الموصي بها</strong></p><p dir="RTL" style="text-align:right">الرجال الذين يتناولون كميات زائدة عن اللازم من ليفيترا قد يعانون أكثر من الآثار الجانبية أو يصابون بآلام شديدة أسفل الظهر. إذا تناولت جرعة ليفيترا أكبر من الموصي بها، عليك إبلاغ طبيبك.</p><p dir="RTL" style="text-align:right">إذا كان لديك أي أسئلة إضافية عن كيفية تناول هذا الدواء، اسأل طبيبك أو الصيدلي.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL" style="text-align:right">مثل كل الأدوية، يمكن أن يسبب هذا الدواء آثارا جانبية، على الرغم أنه لا يصاب بها كل شخص. معظم هذه الآثار تكون معتدلة أو متوسطة.</p><p dir="RTL" style="text-align:right">تم معاناة المرضى من نقصان أو فقدان حاسة البصر لإحدى العينين أو لكلتيهما جزئياً، مفاجئاً، وقتياَ أو دائماً. توقف عن تناول ليفيترا و أبلغ طبيبك فوراً.</p><p dir="RTL" style="text-align:right">تم الإبلاغ عن حالات وفاة مفاجئة، ضربات قلب سريعة أو متغيرة، نوبة قلبيه، الم في الصدر، و اضطراب في الدورة الدموية الدماغية (بما في ذلك انخفاض تدفق الدم مؤقتاً إلى أجزاء من الدماغ ونزيف في الدماغ) في الرجال الذين يتناولون فاردينافيل. وكان لدى معظم الرجال الذين عانوا من هذه الآثار الجانبية مشاكل في القلب قبل تناول هذا الدواء. ليس من الممكن تحديد ما إذا كانت هذه الاحداث تتعلق مباشره بالفاردينافيل.</p><p dir="RTL" style="text-align:right">تم التبليغ عن حدوث تناقص مفاجئ أو فقدان في السمع.</p><p dir="RTL" style="text-align:right">المجموعات الآتية تبين فرص حدوث الآثار الجانبية:</p><p dir="RTL" style="text-align:right"><strong>شائعة جداً: </strong>(يمكن أن تصيب أكثر من 1 من 10 مستخدمين)</p><p dir="RTL" style="text-align:right">صداع</p><p dir="RTL" style="text-align:right"><strong>شائعة: </strong>(يمكن أن تصيب عدد يصل إلى 1 من 10 مستخدمين)</p><p dir="RTL" style="text-align:right">دوار،</p><p dir="RTL" style="text-align:right">توهج (تدفق الدم في الوجه)،</p><p dir="RTL" style="text-align:right">انسداد الأنف أو رشح الأنف</p><p dir="RTL" style="text-align:right">عسر الهضم</p><p dir="RTL" style="text-align:right"><strong>غير شائعة: </strong>(يمكن أن تصيب عدد يصل إلى 1 من 100 مستخدم)</p><p dir="RTL" style="text-align:right">تورم الجلد و الأنسجة المخاطية تشمل تورم الوجه، الشفتين أو الحلق.</p><p dir="RTL" style="text-align:right">اضطراب النوم</p><p dir="RTL" style="text-align:right">اخدرار و اختلال إدراك اللمس</p><p dir="RTL" style="text-align:right">نعاس،</p><p dir="RTL" style="text-align:right">تأثيرات على الرؤية، احمرار العين، التأثير على رؤية الألوان، ألم و انزعاج في العين، حساسية من الضوء،</p><p dir="RTL" style="text-align:right">رنين في الأذن؛ دوار</p><p dir="RTL" style="text-align:right">نبض سريع للقلب أو ضربات قلب عنيفة متتالية</p><p dir="RTL" style="text-align:right">صعوبة التنفس،</p><p dir="RTL" style="text-align:right">انسداد الأنف</p><p dir="RTL" style="text-align:right">جريان رجوعي (جزر حمضي)، التهاب المعدة، ألم في البطن، اسهال، قيء؛ الشعور بالغثيان (غثيان)، جفاف الفم</p><p dir="RTL" style="text-align:right">ارتفاع مستويات إنزيمات الكبد في الدم</p><p dir="RTL" style="text-align:right">طفح، احمرار الجلد،</p><p dir="RTL" style="text-align:right">ألم في الظهر أو العضلات، زيادة لإنزيم العضلات في الدم (كرياتين فسفوكايناز)، تيبس العضلات</p><p dir="RTL" style="text-align:right">انتصاب مطوّل</p><p dir="RTL" style="text-align:right">توعك</p><p dir="RTL" style="text-align:right"><strong>نادرة: </strong>(يمكن أن تصيب عدد يصل إلى 1 من 1000 مستخدم)</p><p dir="RTL" style="text-align:right">التهاب العيون (التهاب الملتحمة)</p><p dir="RTL" style="text-align:right">تفاعل حساسية الجسم (تفاعل أَرَجِيّ)</p><p dir="RTL" style="text-align:right">قلق</p><p dir="RTL" style="text-align:right">إغماء</p><p dir="RTL" style="text-align:right">فقد الذاكرة</p><p dir="RTL" style="text-align:right">نوبة صرع</p><p dir="RTL" style="text-align:right">زيادة الضغط في العين (الزَرَق)، زيادة الدمعان (الدموع)</p><p dir="RTL" style="text-align:right">تأثيرات على القلب (مثل نوبة قلبية، تغير نبض القلب أو ذبحة)</p><p dir="RTL" style="text-align:right">ارتفاع أو انخفاض ضغط الدم</p><p dir="RTL" style="text-align:right">نزف الأنف</p><p dir="RTL" style="text-align:right">تأثير على نتائج اختبارات الدم لفحص وظائف الكبد</p><p dir="RTL" style="text-align:right">حساسية الجلد لضوء الشمس</p><p dir="RTL" style="text-align:right">انتصاب مؤلم</p><p dir="RTL" style="text-align:right">ألم في الصدر</p><p dir="RTL" style="text-align:right">انخفاض تدفق الدم مؤقتاً إلى أجزاء من الدماغ</p><p dir="RTL" style="text-align:right"><strong>نادرة جداً أو غير معروفة:</strong> (يمكن أن تصيب عدد أقل من 1 من 10000 مستخدم أو لا يمكن تقدير التكرار من البيانات المتوفرة)</p><p dir="RTL" style="text-align:right">الدم في البول (البيلة الدموية)</p><p dir="RTL" style="text-align:right">نزف القضيب</p><p dir="RTL" style="text-align:right">وجود دم في السائل المنوي</p><p dir="RTL" style="text-align:right">موت مفاجئ</p><p dir="RTL" style="text-align:right">نزيف في الدماغ</p><p dir="RTL" style="text-align:right"><strong>الإبلاغ عن الآثار الجانبية</strong></p><p dir="RTL" style="text-align:right">اذا تم إصابتك بأي آثار جانبية، تحدث إلى طبيبك أو الصيدلي. هذا يشمل أي آثار جانبية محتملة غير مذكورة في هذه النشرة. يمكن أن يساعد التبليغ عن الآثار الجانبية على توفير مزيد من المعلومات حول سلامة هذا الدواء.</p><p><img alt="" src="data:image/png;base64,iVBORw0KGgoAAAANSUhEUgAAAkkAAAFgCAYAAACvy+1XAAAAAXNSR0IArs4c6QAAAARnQU1BAACxjwv8YQUAAAAJcEhZcwAAFiUAABYlAUlSJPAAAGq6SURBVHhe7f3hjWxNU+b9Hk/eI53vg8R3RmMACAOQMADhABoH0BgAOAA4MDMOgAWMBWDB48F93t/NfUE8Obmq1qquruq9+/pLqV4rV2ZkZGRkZNTq3rX/P7/8BPzzP/3zL3/6x3/yy//v//n//npdPsbf/c3f/mpLhV3/8e//4df6f/vXf/3lL//iL36t/+9/9Ve/1n0V6Pzf/ui//vKH/+UPfvk///Ivv9W+jj//sz/7D5u5/gwd2N96xNfN1fXvfve731pcwxqSk/UN6sm9ZcuP+AJ9MweFnFevmTmbH5+Z87d2yhWyLmftYP6x/dWxHuFoPz8Km+3kiL1nfAd00uZR3/0qmHPs8T/++q9/q/19tDHXrAEbnfH3+NXs96i9ZuxQrhJ//ajv/Ij8FElSKaWU1+CAnx8KFAfvdzxAy89Pk6RSSimllA1NkkoppZRSNhwmSfNVaktLS0tLS0vLz1TO0CSppaWlpaWl5duVM9xNkkoppZRSfhaaJJVSSimlbGiSVEoppZSyoUlSKaWUUsqGJkmllFJKKRuaJJVSSimlbGiSVEoppZSyoUlSKaWUUsqGJkmllFJKKRuaJJVSfgr+9//8X7/Gof/x13/9W00ppXyMJkmlfDH+/M/+7Jf//ld/9cuf/vGf/PJv//qvv9WWe7BXKaU8kyZJpXwhJEWSpD/8L3/w655y/Wy8afnd7373293/zV/+xV8cJmf6/d3f/O1vd8/lI7L1ZSs2o/+Kt0yTV79tMq9ba3k0d3qvuq/ot66n9Vvl7dqVUm5zJb9pklTKi3DIPeMtkjdSSnBQ2qtHh2WeK7NfcNDvkpBn8FHZdFf+2x/919+zHbnq/s+//Muv99pIQl8JW7KpsXeYt+f/+Pf/8FvNL7/88z/98691t5KkrNe0m7U135kIskcS7/46spTz2DPKGZoklfID4bBcD98clEdJkvrs5yQVgQz1DuCrOKT9OuzowP+I7EB3Y5DjZ+ZIpjpzNyfXyjOS0CvcGi86zvln7W4lSUm+ZrskTjMZYouM0SSplPNkf52hSVIpL8SbhGcwD+ezSdLu73uSyDxyyDrAyXRQ75KFj8ieJLFQvEFKUmTexjC2+938Ah3mm5lnkMTFuLv55+2WNnnbdCZJIivJT+a0S5LguTFKKeexl5QzNEkq5UU44D7jQLuVJEkiMu4uiXBY6/uRRMa4DnZvQMjJ26qrsulKT2V94yVJoD95mW8SzltJYMjbmVvJCW7pMEnSknI0Nt0kPHmbdCZJCtGZHkdJUuTt1r6UsseeUc7QJKmUJ+IQ272xcMith/tEv91B5zDdHajeqDjQEblrfzKzjxV9VvI3Mmffsjiw17cm89dDShKMK7LNZcpIUrGSNyzsOUlic4up9+7Nz1kdYCz2jM3N9yipSrLIHkdJEn1WO5FtHHM9SpJmIlVKOYc9o5yhSVIpT8RBlyQBfjpsHag50NYDPofzmjw5OHNITnJgJunRxv1MkshyoGrjWYr7mZDRT/1RIrMmFuZiHnDQuzc+mUqSGOPsZJvrOh/ERhmP7NUe5Gce2s/50kHZMeeA2GXljA7BWNpOHW5BdnyD/muSlLdk63hs7Vme030SmzRJKuU89oxyhiZJpTyZeWDlcHNAKq6TZIQkSWvy4LBWf+tARw7eowN7JhezGDeJzKoTHOQzwdA2yUjmMhMgaJ/nq2z6pf+KOrZaE5pABlnmIpFwPe2lP5vsMM9AB+30X8e6p8OEbchYy5r8hNgrZeqEJL5rkhTfSFnXKf3O6FxK+Xeyn87QJKmUJyJxcdA6jB1c2UfPKA7xeZ8kYa2/VZIw5Y0EPd2vCRocyGvilUP5XpEs7GQfJWxHJcnEbo4z0WDzXTKpzZq4rInHvTLHCUnaZtklaWxAr7SZ12sxx8m01a1+5l5KOU/2zhmaJJXyRBzIDi1vURQHneKQ8zYhbzFmyRuMtV6Z9TNRcJ0EZidzLbskCGRMWRNy1zcbZxK/HNpHsuc8bpUkHbsxyZgYc/cWRzKzm/tVHSbG8Wx9qzMx5ppISbbyFmxXkrjqO9c0yerROh+tbSllT/bOGZoklfINOPp1jPrdmxJIJObbGcmB+13isGMn2/2a4DyDo0QhiWnm72d+9XVkk3tIWpIIPhs23iWspZTn0SSplB8Ih/XRwfjoQT7J3xLNhOcM69/RpOSNx1kyN4nMI/0/QsZcy0eSHHZhz2cmM1nnvKXq26FSPo/EgTM0SSrljUgY7DOHroN7Hrx5dvSm5woOXYf7laSLLvNvYVw/osv8tdOzk4szxI4KG380Acl8zIXs3XyuzHEmsZ/1hqqU8p8kHpyhSVIpbySJiMPWAenAnHj2M7xVSGKx+7uhHw2JpqQmMXKWJE5XSRKbpNR1KeVzyH49Q5OkUkq5iERpviFTJEhrknuVRxKsUso1ruQ3TZJKKaWU8m1oklRKKaWUsuGpSVJLS0tLS0tLy89WztAkqaWlpaWlpeXblTP0122llLfTeFNKeRVX4k2TpFLK22m8KaW8iivxpklSKeXtNN6UUl7FlXjTJKmU8nYab0opr+JKvGmSVEp5O403pZRXcSXeNEkqpbydxptSyqu4Em+aJJVS3k7jTSnlVVyJN02SSilvp/GmlPIqrsSbJkmllKeQ//D1kf/ktfGmlPIqrsSbJkmllA/zz//0z7/85V/8xa8JUpOkUn5s/sdf//Uvf/5nf/bLn/7xnzy0n786V+JNk6RSyof53e9+98sf/pc/+LX87//5v36r/Xe8YZqs92i8KeXr8Hd/87e/7mVJ0m6/flV8WPvHv/+H3+7+nY/GmyZJpZQPI0nyifO//dF//bW4R34F51Ppv/3rv/5H8F1pvCmlfBRJnTjiJ54Rb5oklVKegiQocSNBymt79xInSZSA5V7bSfqVUsqjSIrEkbw9eka8aZJUSvkPBBMJzvors7Pkk5vY4e2R6yRMWO9D400pXwuxYL4Vfib58JTyaLxZSZLk1254RrxpklTKN0XwWxMib3skN0ruJ/44W7mHNuKHIDs/xbkXuFYab0p5PbsYgHxYsieTcEzs75k82dcSlJC3xrtYoZ9n2fPKLpGBN0IzfkiuMi691r83Mg/yMp9nxJsmSaV8U9aECDPwCUICTOrSXlwQrIK62Q9pp/8McoLhR4NWKeU57GJA3vLkg85MfpC3NfkDaQmJZETdTE7cz7rgPvEhZcaTIP7MZ+v9LgFKm+j8jHjTJKmU8isCzPqpTQxY/7WIAJdPfp5pk8AlWfJcACNPuxmAXTdJKuVrkv3sDU3+0cX6NkhipX4mT/a9PS8OkJE9vu7/iWfk6HdEkpx8CJv3iU/zA1p0S8x6RrxpklTKNyWv1BNQBMUZcCDAJPAlJijzNbcgSg58SpztlBkkZ9tJ2pZSXscaA/L2aFfWZxKSJFIp5CR5eaTcGv9WEafmfT7sPSPeNEkq5ZsikAhyAgl8optvkuB52iQmKN4ShSkjr+Jnma/btVtf3yNtSymvY40B9qYkR1HnA0725owBSTzEjNTljY3kaU1adkVfcmbdHEPRZo6x3qf/HG/9UPbReNMkqZTyKwKNgBmS8ORT5o58arzVZrILWGi8KeXnwocjCc2MKa/mGfGmSVIp5VfWT3WKxGn9FZz7+QlTIPwokVVK+ZpIesQDe3++rVmZb4O0X99OfwWuxJsmSaWUXxHMZvLjE+BRgJMoSaokSM8Igo03pXx9xAdxwd73a7UjtJMgzV+1fyWuxJsmSaWUt9N4U0p5FVfiTZOkUsrbabwppbyKK/GmSVIp5e003pRSXsWVeNMkqZTydhpvSimv4kq8aZJUSnk7jTellFdxJd40SSqlvJ3Gm1LKq7gSb5oklVLeTuNNKeVVXIk3TZJKKW+n8aaU8iquxJufKknyJVd0Xr+KfH4D6PrFd/4Pqjz7jK9Pz3/toBz91w3aTJ19CZf2V77J+LPn8Qj+ywpzWL+x+Qw/6lpO8j9S7/Qxj3wZW9Y/dro6zlfCmjxi+8y3lKvYR+JM9oq48+gXnPLdyCGDrHvMvfwKjDeZOj8bXwo5/5/GK+gbu5y15S30J/OWHM9WfVd74Uq8+WmSJIaRXDCIbwOdOHQ4kvmsm0d7/T4LzmtsY+wcmW6eRS8Hpfac4UqSdGse7LFzFA71aBJzD/Nh70c274+6lqudBQjt1fsZ6E2GuWijj5L5ZO5fjXzL9py7efEh9dN3r/KjxZvydeBziv2UD0qPfNMz/40fksOP1/izYv+mj/1Lj/WQntg7ZNrjjyRW5jjPhVXnZ5I4payx9h7sTyd96XjGljsyX7L0Z1/yduxsob/7tU/aneGnSZIc+AzI8SzMikU2n3Wxs5iPOOwVLPR6sOb/wtmNre3cDPc4mkfkGGduotiD43GkZ2MtHtkU+BHX8sjOMBdlIgmia8q0lfnv5v0VMLc5d2vgns6uzbNJUnkl/C8xLDFgjQ1nmXs1h/I9+Lv97CD20164BV2VW0kNWcZfddBvPRemzo+SWLvGTuM/ej7MOHnPluy2PmcDOl35wEjGjD/WYrUXrsSbHzJJ4lzrRrCQ0VlZM0dt1a9OkHqb64hV9q7ccnhYqNXZOJC+O+fxbHdQGofDHc1vnYe26owxN69rxTjaTOh5y6HvEV3u2QQ/y1oe2Rnq1o2u/1EiFL9Y5+3eOLskUGBIQJp8dC2vYqxdkmT+t5Kn2L6Uj7CLJzv46a7N9F8/z+yd3QH/DMzF/p2xxvUuSbq1t85C9hr7yJ3xTOy5Z9sw4+Q9W5K5xs2spXIvJofVFjt74Uq8+WmSpOAg8Wx3kKjfHaDqdwfMM1mdLajbzSVzXA9KG/JI37WeDXIQc5bppPnUoKxO5NlOp7OY63TUW/wMa3nLzlC3JqKZ944jm5CjfpVvfPW7YHBmLZN8xW47e4MMY5BHxwndsAYpWCd9ouPReiqlPAJ/5Fd8lB/FxxJf11hhX8RnJ+riv3z5zFsM7bIns0fJX/dIIF+b3XlwD/LXfT51fjaZG7uKEfRWYjv15urZelbRKe3O2nLFupmvMY7i0sR4M9aKafquZB5n+KGSpBwea1kPgKMNwHg7x7QIRw79LIw7Fw9xsJ2uSRDWzb06wWSdh7ZxTNeZO2eL47ie8ow7N/1Vskb37PkzreWRnUOShBlE6LjbvGAD7VfIMe5qI2soIK3J4ZW1pI/+ZO/sDWN4PoMfXNOXHsaaAZsO1kQ/803Am7ZA1r+UR+BT9mD2Dn9W+KKf/G7CZ3d+qD5tV18+Qh9j25t+Gs/1Tr7YYB+nz8RYayJAh1k39Qu7ukdYx0JiHZvOublPLIid6THRPrHnjC3X/mHGDtdB+7XPagsxbRdX1O3qd/x0b5JgYY8cdFdv0de6Z5ODku4hm+oIz89s0rDOg8NkHZVsAD9n/ZFzPgJ9b81p5WdYyyM7B/qon3bW98hOCT6vRDChp5+7sTNH9vVzXS9rYd5rMDTPrFOCnPu1f2xXyiR+eQ/+aT/xq/inGBG/Sl32LJn8cI190//5cg75W2jDtyMbkS9WhMRde8gzY4WdPrs612tCdLRnwxkbHtmDTek7Y1psvJ4jCpsHdom8e7ZMTJ32mrCt5zNmxu4Tc9Uu83W/tkH0PcNPmSSp3zmN+t3BtDrGZ0GnLN7qYPNZ4DBXdHvVPI6Igx6ty46fYS3PIHjMIGpt5/1E/dGzz8A8BEJBh10Fy+mbZ0oCERm757Ps1i3PSpnMgzUJ+iz8LtfiD/+NL+bgnc/n/VGZB7s+O+zPR/aJ8mi/tcy534p792z4SElMvicvydUtWwZz2MmYZY2LR7ZkG+Mpc/4h7c7wQyZJpZSfi8abspLkPdcSoCQ+Rx8iHMrrYZzE/yrzrciPyiM2fASJyK1E7YwtfXii21m0zdwm5qje/OjkfuVKvGmSVEp5O403ZYfkJgen5Mcbgt2byCOSJHz1hEdy50C/97blET5qw3uQaQy2voq+EixrlDeAtzCG9op48ai9rsSbJkmllLfTeFN2OATjGw7RW28rViRG+u1+Xf/VSKIg2civqJ7FR2x4C29q6Ezuo8lKktgr88582OxRYo8zNEkqpbydxptSyqu4Em+aJJVS3k7jTTnCmwO/Lnrm39B8N2rD3+dKvGmSVEp5O4035Qi/LsuvZB75u5dSG65ciTdNkkopb6fxppTyKq7EmyZJpZS303hTSnkVV+JNk6RSyttpvCmlvIor8aZJUinl7TTelFJexZV480MnSfm+hPWLsdxH//XbNv11f5595HsWjvAdFJF/5bsj6Pysf3lAh/U7J45spW2+NyP98sVjV9HPGI98z8ct/Y7s6Q8Q/SGiZ2e+iOwqt8a+xbPWMl+YlvWZqFvrH9X3GZgvfa2DPed+p58/Ht394Wj0Lj8m+b4bazj3v+us7RpvP3PvTo72424PPZt37skda3zN/aPr9K75rfGGHusaq3tGvPlhk6QckDlIpiEYJ/VrksQp9PssOIqxjbFzGl9wZmGnvnSk69VvheUAq9Mjdgm3bEVG/h8y12z3qLOb1xz3LLf0u2XPbNBHkrIzvHMtbXjjqvNsxbhr/T19n4250s98FWNnXPpZnwk7qVv3JCKj/JhYV/6oTN+3N/mFej8DX3Av9vCVz+LWftztoWeTPXyFXVx5BvkQmw/BSYzs2UfX6ZH5PcpRvMkar0nSs+LND5skWegsmoVaD8oYbjXQR952XIFu60EVnTjieoAcHYZHkG0Mc5/Ood4Y6rPJbtmKHtqneL5zqnsY99G+99YSO3uaH51XWz6bd6ylQCkIsIX6lazbLpDu9P0MosPReq120c6cdj5CjlJ+TPg7n7Pmu0PTuisr8f3P5Gg/3tpDz8I+3u3fI27FlY9innTJ+tDNWHM/Xl2nq/P7CEfxJjZbk6RnxZsfJkmiywz8DBIdlWTHIYY7MujafrLK3pV7Drw7JDiUYh7rpo0DrNBF23UjqzMHTkBmMK6sf+p4y1bso26101V28z3CeFfWEkfy1c/5r/yoaxkZKWufrBuZK1fW4iPEz/xcWXVIgNbes5XMs3wtrO3u0FyJLyjrfgAZu+TJ/rl3yE7ZR+UWR/vx1h4KHx3b/LRZ9697dlrj7q24Ej4S02KL7Md1ba+u09H8PoOshZ+TXZL0zHjzwyZJE860cwp9dgfuLVnPwkLmwAsWzaZQ1oWj587eHHbVV/84rHnH0bN5yNJv5xw7W+lzK1Dcgzz6nN0ot+x/tJY7e0L9mSD+Ed6xloFN9dFukvrduh3ZamKce3YTfBIwzWmVSYfMaZXFJnMdXatL8FrnQ4ZSvhZX9xc/iT9PrP/u0E/MOhs7HuFoP97aQ88i81vfZrCH+tW2t+LKM0hCYV13c7+6TkfzW/nMeJM5zbk8M958+SQpesyyHrAMZ9FXLPbusGC81TmejXGns1mkBA/XqyPG2VZ2TqsuzuQ6c2SDjJHAcMZW2q1OdJY4IT3ukfWb5exarvYMNsuZsT/CO9ZycmRfY+z8+MhWE4FlN5b5RB9rYwxrzM5HQZsc7aaO2s772CRl1Tv15WuQQ3SWe4cc+I+26/omHq2HrHv1nn8WR/sRO12fSQ7wFfO1R2dycS+uPAvrSKddnL26TkfzW/nMeBMd5jpmzVPWNU79GX6KN0lZ2NUQjMnp1gXnfGvds1l1SvBIWQ897XZOu0PfKYvsOPF0RHOPA4adrbIxH4EuydjPYvyra3lUbzOtdc/m1Wu5cuTHuzoc2WpinIw19U/fPDOG5+pv+UkO1fRbk6SJtqvemX/5WlirM8nRRHxd/T/xaecTu/bP5NZ+PNpDz8IBfnZu9k72wZGtnkHG2cXgq+t0dn7GTGyYsp8Rb3ZJ0kTbj8SbnyJJwi7xYbw1ScBnOd/KbnGOsMC3DrUzmFecDQ5XNliZtvLzUXsYiyPfWpcdj6wldvb8WddychSIbs39nr7zk9pMrMH+2f9XytSR7F0bhfyVPCtfC2t6NUmyt3e+yc92+8KB+Jn7+NZ+/Oz48exY8Cx252K4sk5n5/eZ8SZJ0lH5aLz5YZKkUsrzkeiuh6D7Vwf2xptSfn5+xHjTJKmUb4xPhz7h5Y2jT3m3XnN/Fo03pfz8/IjxpklSKd8cr62z313PX9m+isabUr4HP1q8aZJUSnk7jTellFdxJd40SSqlvJ3Gm1LKq7gSb5oklVLeTuNNKeVVXIk3TZJKKW+n8aaU8iquxJsmSeUhfAePf7a5+x6mz+Rd45bPpfGmlPIqrsSbJknl139d4MvFzn5Zon/GGf/IF4SdRXLjn33mywb980//wmH3PRnGmV88dm9cddpcxfd0XP1CzPJcsq6llPLZXIk3TZLKr4mFZOXs2xnJyPqFYGeQCBnHN6BKStwbmyy+tn4Tq/v5ban3xiXjkWTHGOvY5bU03pRSXsWVeNMkqVyGX1xNRiRE+h0lI3lLtHujFO6N+4hePwvs6o2cn94MTjt4QygRzJtCbV7560q6zOR2918iWDvlK+K/Ylj/O4bYlM7r97yYr/p1ntr5kCDZX9/a5oPCR/+bjLypfQR9n+0nV/Xhw7sPQjs5n/UdO9bgVhxaoW/220fs/0ymbcTWs3FRH33jA1dtcY9b/x3KGejC3vbQR3zzSrxpklT+I0EJrtVxSEFTYLfJ3McvUrSzoTh/DoBdkFA/NwgHJ286urFmm5k47cbV14Z2b2w/ZzCITurJPtpUkRcEBvrqS/5HNuMK2WQ+g+iZ+QkeWYs5p9hR21zP+X42dDMmfRXXa5KgTvmKsJs5TMxDnTL93bz4TZKeOU/rrmQdAv/Wx7qt41yF/EdlmAedycie+6ifrPrEbuv6B4e0NivkzOQpfsxuR7Jg72pjzJ3cFe3JNf8zGFv79Dlj/yOdyFL30SRrtY2fZ2XSR1/zuGqLFbE4cTTrSt6t9dpBj8Q0ZSaljxJZZ2iSVH51uLnWrjklB/csyQaycTi8a9jYNpWNkIA/N2Xk2xyKtu5TEvzIzDiYeu3GpR9ZxkxgmJuHDp7dC16zX3TQJ5+qjPMszJ9eZwOFdvRW5iGhnp7WZiXBSElwModpp9jwFbBtbGjuO3tG369I7DnXzHqYl2dzDdg387M+7A99Y3ft9QtsYm21nf7/CKufXCF7zM9n+clOH3O/Ktc+XOWw89zvR2hjPmfaxgb2ylnoFd3O2n+nk2vznLHzHmTs2sc28bszcwcfzLo/YosVa62QcbT3g3bsN/cZ1NMje+kZkKecoUlS+XUDzbV2zZkTyHbPs+k4v/sZ9Dj1DPY2fg4SAWTKdq091nGujjufBxtOm1XWZPajzww6+nr+kUDxUYzNRrETMv9busXW2iTA7Oy2w/Mzwf4M0/bmQKeVzOUrkoNj2plPR2eBPcx1URxi4If2ROqnj7HJ7LMeElfYJRM7tFuZvn7WT+6x0+fosDNvbZV1H+/kzNhxD33P2HW339VZ46zPOibZsedZ+2PVyTi7Dz1HTJ9a12naxvPVnkdk/tZoZ4uPcLT3J/bFOhc2pUds/AzIU87QJKn8XwmE67mpbj1fn2Gts5GzYec15r2f7sPVcedzCDjqZtkx+83rsKsL6neffm5hnmkvKJCfw/QK+gg6bLY7eIxB9gy8MwjeImuxzkvAPHsIhBy4YK+5xsHztPlqxI67w8Ia7OYDfjF9PVjz3WGYcW6tzepv8Z8cPtYmsq013WYSB/KP5pP61U/O+uktfRCd1oMQ+uibhGTaYZd8qNvZd0Ub8nbzNQZ9jE2nzHu2Tf/Ycl07z3OAr/M94pZOZzEWnchZ7TBtY27r8yPm/He22EE2PZRdW8/569Hev4e+bEqX1Qduoe3ONlCvnKFJUvnVeedau1YXbj23KdzPoCdQJkhitp/XCahxYht7Bphb4wrW7nNYRI8jvciesiaz3xpQzgQK85jzv0UOKGOQSS8/Yy/zmYdgsOHnoRGMK/AkyAfX5OTAyeF2Zj4wPrlrgMmagT45HELGnWTOnq1rGtTt6r8KdNvZLHPbPePLq33Apmy7rjF2Nl+Jv2m3+go/yZjxLT/j30HdTjfjazv9JDL8nPt65Z4+gYz1sDNeDjVltQ8Zax/2Xesm9NUmeq92JT/6kqPMeYf4eXRbbUlu7ELGzq7hnk5kr3XkrXtff7qoN4dVp2mb3ThHsAW54sXOFur4X66NTT9tXK/rlv1hfDq6vkV8b8d6XiBrs6KNkjmsMtXd0yU0SSr/l/O6npvu3nObMBs5n6ynI897G8kGdq+fkntyZzC4NW6c38bR1xjzeZIoPwWLPIcxjJvNP/uRp61n2YB0PkJASF8/Z4A4IvPNpk8xp+gWmSBztekkAZPckOAF/fLsKGiEGRBj1zXo0Q90XGVFl7mOnkeOPuk/0Uf5qqx2mExbT+KD06YgR/1uPeN/R2PFhtiNm8M+Y6Sosw5Zq6zTqlv2hXae+7nz0x239JljH9kF/NSz1TbkkjNxf7QnQB+y9DWvuT/gnq3NL36Zea+68Wf1O9/VN/POfI+4p5P6WWcd6bjOkxx19NzpNG3jeXxmx/qMfup2tiAz+pA7n0XXufdhPtrHxkfEZ63HEeyjTcYg0/30yayVtrHPbo7KGZoklf8IWsG1unDvOQflkDYIh8zmDJ7Z1OC02rnXj5z0mzKRDRDWcT2PrGyM+TwbSsCYsrTVL23Vz01kk9JHGxvc5j0iOpA5g2OC4VHJ3Nc6sN+sP1sSsNYDUsn8jHErUMVma9En13N92We2OyoJ/PTYHSJp91VZfXpiTkfP+cHOf9hgHjAhe+mI6W/TT6yPvvF1TB9Uf8avyMb0kyM/Xbmlz5mxHynssCP7Me3Ma/ZTEpdy75rOs83ZkvWf9l85o9MzS2yTtdjBB2fMhL7qHrXFrpDFLuZ/C/rs+s+y7o81BrHrtLOym6NyhiZJ5dOJ4yeQnMWmeoUPGuMosJ3FQSjI5lpQyOGyOwwn2uZwAjnrpn4WAudH5xqi960kcoUP6LfCTq9Y658Jhx9fmftq9yncgXF17+38ZPXTlbP6fDXoS/ckFR/hFfOd8YHu9+LXLZ30X2PNs2yxYqzd3p9oc8WGt2KQZxKofECbXIk3TZLKS+D4/MmnABta4pBPMTaG+rkxOb3gbsN+JkngnhEUbNYEHHOk+26DTpJc6Wu+rj97zo/CVtZKydr4OTEfz6/SeHMNB8Bq+x38kG/dO5zuET89OsDO6lOuIS7ZTzMJsg6xdeLMLkk4g/XMmxkyxKtXxx9zNJ+8ETrjq7di0BmuxJsmSeVlOGRtBEE7/sXJs+nn5sgG0OezSIJ05ZPLLQSsOa97ycJMHGey9Bmf4p6BtaNj5uh6Dc5sau5X34RFZnkO1iFr9dE9NP20vBZxcI0L1jMx9KMxUsyde9p4jyZcH8G4xp/J4C3Ygg12MegMme8ZmiSVUt5O400p5VVciTdNkkp5Ij4JeYvy0U/v343Gm1LKq7gSb5oklfJE/Eoir8ff8dr6R6XxppTyKq7EmyZJpZS303hTSnkVV+JNk6RSyttpvCmlvIor8aZJUvkh8assf/fz0X/aXL4GjTdlR/d5+QyuxJsmSeXL4w+h5z/Tdx//9E9gVx75J+hYxymvo/Hm83l0XzyCpCZf45F9evWfl3/WPi/lSrxpklS+PBIXfwwdEnCP4Ldnv29jso5TXkfjzefz6L64isTFP1zwjxiM502Qn/atcjZR+qx9XsqVeNMkqfxw3AuO957/jDiI8sndp3hfZDkPI/bIl1s6xD5iH4mkcubLBee4Yfct5I03n88r9gU/NM7ui1T5I//crf+Oe/q+Yj7fnbwRtN+nrV0ngXU9vwDX9Vzjs+v9LKZu+Gi8aZJUDnEIrs4+D0b3qXtmu5W8dk8AnsUzG5kc9/km2rmhyUy9zX709w0ZJwj0gno+FR/1uwIZZJrLRyHL3OisCAwJWJlrcK3OnMznI79WJJ+tyLr3VmCOCz/dr/3UKd+F+Bo7WLf4WMhztmZDz6dPW7/p0ztu7YvI54eeZV3Uh7QJU55i3NWP1ySI/krWe847ZC5KZGaMFP1uzQdn9/m9ebDFuu/pq238OGi31pFFpvbzOV1Tn3GPdHwEuq66PIo1mXqu8SLzMF7WLnNJX+vhuet1v38mU7ej8dUpZ2iSVA7h7DZ5SACKw7nnhM9utyK4xBdtRNfaZVOSKUAITgnC64HimaKdTbRjjkM+ffQR5PWbun8E48zD6B4JrvShS6AjfWcd2JOunglU7vXN9Wqfq5DhYGebexjH2Fnj1QcCnWL770B8jV9Zl/ht/CLPsyfYzT07xje1jc/vuLUvpnzXfGg+R9qEKU85ak9HJYdVykw24juR46fnqf/MfX5rHrf2vXWaMtM3+gX97Q/1ZGR/0tk4GfeWjo9gHPqfRXtzU6YdMy9zyL5d0X7aRXv32mde5n+03z+Tqdsz4k2TpHJINgvHd23zJzgniNloz263wuk9C66zqSNT/zCfB2Nqs8qazGc2lg0Wop/x3oHgp0z7CEZ08nOHtuxrLgJZ2NlnkgMoZV2TjKtMu+9Y7W0OHw1aPwOxi4MouM+65Hn8jf+6tzbsd+8wvLcvIp+8MJ8jbXBmn/GL+Jl50TP7bvad/fiWe3tN28ls96x9fk/OrX2fvtkP5rrbexIERfsdZNLzSMdXkrgy/cA9vW4lcKvu5qM9+2XdcbTfV8jLGnyUqdvR+J6ftX2TpHIIR+cDNpCgpwgMijoH8Ge0W1k3pOtsqPUZ5nOQr26WHVOWn1MGdnUJDmv9LRLEc23etwLSEcbO3Nhyh4Dv+Ux0BA3B4wjP9aET3WbbHGr0dkDkWdquCVUOFrrCvHfrrI3yXWCHdb7u4xe3ns92R3xEfphtzrSfvjKvZ2KSGDATiOx99dPXpvwz45/Z5/fkzOsw6+yNJHTq6b5intHFvsiemPOc5YjEyCtM+2VP0ucq5NDtaPys6cT81E0d2I0O92CvXcJJ1roe95i6HY3v+ar/EU2Syk1sNEGBo3G+bAR106mf3W7C0acvus7GSf8cwtkgeZ77BApjTFmTOc6aSOjvGXkr6jLeGQSEbFz66O9nZBh3jg2B9l4itPZxr57NlXAvScI8cGaQZWe651l0TVnXcCZVmDaeRN53YWcH9/GB9fn0vxzUt7i3L+6Nb7wky7gnD/N+XvO99F3lTKIT2ZgynrXP78m5t+894//aZw8foS89yIT2c92OdAz631vnCd3Is+eyH5XEDXO2FtP2rtc9G2IrMlbWfc0+5ke+n6nPmt4j6xA7B/KinzFXXbUXqyZTt6Px1Z3RC02Syk1sUk4/A0Lu5+Z5ZjtOLrBkw6yO7jpBzUZwT67+5Mzn2eh+ChZ5jlvjRE/PsjlnojHRL4FnF1BWyCNbH+OlJJj5mcAaMrcjEnDJRuZNf+Pom2dkxz472FQb/dnhCDoZJ4dgCl1ij6yPdjDuOjek73dh+lpwn3XJc3azhmwau8U3tfHMz9WX7+2LyJ9o48DxjKwkyoivHsmDuvg/n9CfL8c3Izd+Dnqrp/f0WUz5z9rn9+YR22qr37rv018bbbHantysGxtoCz/ppj7rGR13kKsgdr2HMfSZe9I4iJ6ZK+iiTcZZMa7n5jOxHsZij9gkOppbro2V8XfEZtBPmZATfyHLOMYOnse+Yep2ND45yhmaJJWbZBPNwOZa3XTwZ7azYTl5NmY2R3A9N63n2gsM+q7PbbyMOWXdG0cQtMG0EexsuhV1xiWbnMjyk6xZooeS+c9gNm1izLXPvTIDDN3nsxkoXM9As0InRbspY1fMfx1LyZrOIqCx8ZxnSJvvQvxj4n71xfiB9Zhrxobz2erLuLUvduPP9vbi2mYnT13gf55Bf23V8ZH4w7qPtIufaZ/DFerOzgfZK8bS1jV2+/zWPO7te3X6ZD1W+eS618Z14lrGVbIXouMO86BH9hiSAOi3K9pj7snUwbiz/dWSdVTYAfGTWWIbc9TniLVfSnxCif0Q2+/KjJXR7Wj8tDtDk6Ty5bkXTJ7FR8cRmBIoBU4IkjN5OcJGzgFBhn6fRQLujgT89WA4A/slOK2wgfkpuwSt8eb3eZXPfwT6xd/hMFMXP/5RWOfx1aBb9mziivsz+3Tdk+LKK+d6tN8fIQnildj0jHjTJKl8aWyIfKL6TJ4xjg2Z5Ia8fOpJYDsiB6JEgg6u1b0D4z5igyRX81PfFRpvfp+vmCQ5XK2zwk93B1beYPB97fmDYj76KO/mzDy+EtlbOezFGTa+l4ymn3bmKTZ9dhx9JvROoT/dV/8xx0dizpV40ySpfGmyOR49fM/yjHEEWoEoe8dBYRMfYay0z0Hieg0Er0QgpoOEbdV9Zxvtkwx+RG/9lfLvsP29Q/DV8FWHrnVyfbRX1POftFXsLXXvSv4nZ+fxlbC3Yks637Lj3JN8KHHJnG/Fo6+EOdBZMQ+6u16TWfPz7GqSG1ueoUlSKeX3cGgkOKXskqZn0nhTSnkVV+JNk6RSnohPNHlFXM7TeFPKbcQUb5Dya7fyOFfiTZOkUp6ItzB5NdxE6TyNN6UcM3/95K1u+RhX4k2TpFLK22m8KaW8iivxpklSKeXtNN68H38cPP+Ieb1/F96i0OPqH+eWcsSVeNMkqZTydr5bvPErk6+QgASJCPvn713W+7P45/XP/Gfm+Vdayvrr62ePVb4P8akzNEkqpbyd7xZvzPXWP+OWREkCJru6ZyEBmX/rst6fJV9j8QwkkWQdJZPPHKt8L/jNWd9pklRKeTvfLd6Y660kaff8Xp+PsP5Dg0f/4cEzE5d7sp45VjmGH/jV6/rWThLta0HyL3on81e1EvtH/dabzCv/EMaXma5JtbeRK/zmrO80SSqlvJ3vFm/M1cEhoDsAHAS5jy1SHDK7utQ7qKaMkP+6IocMHGzrG6J7v2pzyJChbh0DGSfP/Qx0M546h+zuTVhskDY5lN3Pgltj0StydnpOVjnTJg79zJk+2qrTdj2oo+/Kzva4Z8uPwI70ybp9hLkmyvr3afE9czB/1+aM2Eqx/trk2SOwkfHu2WqOG12jm2eTtDtDk6RSytv5bvHGXHNgCv65RpIUAX5NXGadfupyUDmI3DsQHBKu/dQ+h4ZkwFgTfWeSsN6T65AiwzNy88Wi7jMHz5PcgB6eqaODn5njZLYhV9E3Y6lXbo2FHKQ7PSf35EgOzF9fz7VlA3abCY9n0W+Sej898zPcsuUzIPOKPHM3J2UmEuavjo2OkJB5bjzzUIyf+bsm0/UtOfcgP/5xD+1W36XnSvQ9Q5OkUsrb+W7xxlwdvgn8DpE5f9frwbLWpU8O4RxIDuEcXA6JefjtWN+G7N6OkBFdpx7aGiPMebjOHBUH2O7AyiE9kwlMWbg11sRYtw7nW3JywGeuYAvzyLMkIZKmeSCHe7Y/suU7oIf5KdGJfuZLN750xOonseNaf2+OxtAmJfbF1GXnOytrkkSPXb+MdYYmSaWUt/Pd4o25zoNjHtRYn+NeH8w2Dp8cMPPQmuRAzwG53sPBo26WjDGvMXWSJMw+u0QIxpJwpE0OyXV+ro/GwpxvymwfbslZZWLWJcFKEnaURBzZ/pYtV9jBeDNpuAf7pn2Sj5kQnoUMyYY5HI3v+epX1k+fyZo0rXhOz/SdbV17nmQpuqTtqpv2ngW2XfVBbH+GJkmllLfz3eKNuc7DcT2c1+e410ey4f7ojcwuQXGArr+emPfr25McvNFjPdSS7ED97oA6gv7Gdihind+tseB5EoJVz8ktOZnvTBLJjE6ZE7ln5jZtf8+WO4y3W7cj6GQ+kgo6m4e6zMezVZ7xpz0mEo7IWSFL0heydspMzNwfyQ9Zg9X2sVmKe7JSpq9CnfFC7L8SeWdoklRKeTvfLd6Y6zwc12DuYHMAORRyqK516eOwVTcTjDxXn8M4bRxIQfupx3qfvn7mAJq6k+UgjWw6Zh4OO9fROYVu5LgGuZkDeWQg8wu3xkLso9/Ucx3vnhxt1etHL8/piLxBUjcTgTnGke3v2XJHxiUz+t9Ce/PLWCnGoLt5z8QGq09MrCE99VshJ/olkdSenuwT1N+aY8ag57TpCj0zhzm31MM46uY92Svpe4YmSaWUt/Pd4o25OshCDrUguOfwzgGz1imuU+fwyKdwB1UOHs9zmGnjUIGD1/McKOt9cICq1y+JT3R3r94YDrjoFKYeOSyNo31k0GnOIcnAapN7Y7n3jIzMhYx1vHty5nM6x3Yh9tAuzDGObI9btlwhMzajZ9bFtX5HRXuyjT3rELs8q5AHNp/1MxEzh2mrFX2V2OyoaIPd/Ne+sZuyJoVIuzM0SSqlvJ3Gm+s4AD5iM4eNwzqs99+Fj9rxFUgQZjKbJGhN4HZIGJLMWGPlldwaj17msSbmZ7BuuzdgbMNeklX22SVoV+JNk6RSyttpvLnORw/3fNoO6/3PioPZAerwzFufo183fRXol2SD/nnzci+58BaFj/i5ewP2bvibeVwlyVXeOl7lSrxpklRKeTuNN9dxUJx5k1B+HzZzMPM3B63k4ZE3Ga/EWkdnRdJzS+fMUZEUJVn6akkw3ejlDaY5TnYJkPZJ9na/RjtL7HiGJkmllLfTeFPK90Qy5M1YYoCyS5qeyZV40ySplPJ2Gm9KuY2kwR959+3hx7kSb5oklVLeTuNNKbeZv0I7+hdx5RxX4k2TpFLK22m8KaW8iivxpklSKeXtNN6UUl7FlXhzN0lqaWlpaWlpafnZyhmaJLW0tLS0tLR8u3KG/rqtlPJ2Gm9KKa/iSrxpklRKeTuNN6WUV3El3jRJKqW8ncabUsqruBJvmiSVUt5O400p5VVciTdNkkopb6fxppTyKq7EmyZJpZS303hTSnkVV+JNk6RSyttpvCmlvIor8aZJUinl7TTelFJexZV40ySplPJ2Gm9KKa/iSrxpklRKeTuNN6WUV3El3jRJKqWc5n/89V//8rvf/e63u+v83d/87S//9q//+tvdf9J4U8rPz//5l3/55U//+E9++fM/+7NfY8nkv//VX/129Tj//E///Ms//v0//Hb37+zkXok3TZJKKaeQ4IgJM0lK0NslPiv6/eF/+YNfZayBq/GmlJ8fSYx4ofy3P/qv/xE3xBax4aOQK474iSO5V+JNk6RSyikSgGaS5FObYCcYncEnSDLWT3uNN6V8X/Lh6cyHrVvkg1w+hB3JvRJvmiSVUn4PgUYys7JLkq7yl3/xFx/+ZFdK+XFJIiMWBDEhb39u4Vd0iRXK//6f/+u3J/9OZHtjhSO56X+GJkmlfGN2CZE6wUUAkhAlKXpGkpQgt8povCnl58H+Fi/WJMav5+3zxJIkM95G7z48TcjUJrEicibGU59xj+Sm/xmaJJXyjZkJEdbX0vMPLI+SJM/XX5/BJ8VVXj7pCZaTxptSfh7sb7Fj9wEsiY24k1+LqZvJjHi0/mG3OvISK5S1jaRLvXGwyg3pf4YmSaWU/2AmOxIcn8QU7JIkbdStf4hNjvo1eUqS9JG/ESil/FgkDvjglL2u5Fdukp+ZzBwlN0gcSlya5E1Vxlvlhox/hiZJpXxjJC0CicRH4rJ+MktSk9fniQtHZQ2Cu7ILbnlWSvnxEUvEiyQriSv58JSSN03ihvYhyc7ZssadfAhb5Ya0O0OTpFK+MYKWIOJVtuv1jVDeFPl5lABJenI928z6WfIqfJJnpZQfH/FCLBEPXCcZmogPiQXazbigjzdAM26k6Ld+YJtxZ461yg1pe4YmSaWUXxFMBKD8vVD+rkDdZ9N4U8rPSd4K5e8eE1fU5Q+3ZyLjuSToGXFnlyDhSrxpklRK+RVBLPt+lvVXcGfQR6DzifAMGauU8vOxeyu0JkHrr+Lyq7rPIGOcoUlSKeU/8Mkre1+Sc/RJ7B4+IQqCZwNd400pPy8+gCVREheOPngl/jzywewKV+JNk6RSyttpvCmlvIor8aZJUinl7TTelFJexZV40ySplPJ2Gm9KKa/iSrxpklRKeTuNN6WUV3El3jRJKt8ef2S8/lcb5bU03pRSXsWVeNMkqbwcScnuy8XeBT+f/wqLbvn+jvIavnO88b0wvvTuMxL1K7I/e1/6Ogj/asm/brLW/rXTK/baV4s31qPx5b1ciTdNksrLyfdhfBXoMpOk9b58Pt853uSfR5/9TqkrXJH9mftSUkAPXythHPd0863MxvzMf/L9leKNZJUdHv1qjfIcrsSbJknl5XyloAW6zKRovf8RcOg4cHxKdyAKwvPtgfkkMDucPjI/B51y5tP5HDf4JL3SePN+rNVnrAHfJPcoEeKPnn/W25XPmtd3xlra/36yrzeWIW8vw26/fyb0mf+90kfjTZOkLwBnW51qHkDuU3ev3VlZO6x3DtC8CodDbt4H9Q7lPJufVskixyZanydoOcQ58072JDL0WduSYT7q8yVl6rRdD2fP1zpE17DTfSYcH4EN6PGMA4Esc6evwpb0FqTcS2SCa3VZS3N7FPL5CVn37DLHhZ/u137qlO9IkoQQe7EdX7GmsaPieu4113x0Po9/7WSvvr3bl+o9V3dmP809avyJdjPmGI9+cw76zDbRe6fLvA/q1zgQ5ry+Srwxv3BrvI9i/GfJI8uc6Gm92NLc6axkPc1HG3bSx7V2r4JuxjT20fjqlDM0SfoCcCrOF7JhsrDuLfaZdu7PyNqhnQ3FyRKk1vtsbjLIEuwcmtrNcbX1XL02MwgmaHmmbpU9yTj6kGNjahvIJYcOnmvLTuR6FjzTbwbmoH4GXPdHuj8DY+3meoT2dKCTeYYEgFkHa51gRm/3+uZ6ne9VyLAObHMP4xg7/rf6cKCT8h1hozl312zGxvxE0Ya9FX45fZs946vKXN8j2TvfTlt11ikJBW7tp+xReqqfvh2Z1l8xrvsUYyAyQvppP3XZ6Qb12q5xAFOWedDP/dQzvDre3Bvvo7A5/bL/7mFe/EmJjtCfnvGViTo665M1ZgtzN/Zuv38m9M6YR+PT96ydmyR9AbKhOFg2nmITczTPsinvtcvBeU/WDs84t765j+PnPhtHfYIQItuYcD031AyCZHieAIkpe7KOk76IPYwdMk6eZa50sXl3rGO7P9L9XdBBmWtnPnQ9mpe29GbDOZ91vis5RFJWf8m4yrT9jrleMIePBq2fjdVGrndrytb24r094D7ru5N9b19mv+3G2e0n60nODm0ynv2ubXSd/VY9c78+v6XbLg4gbb9ivLk13rswJ2UmkZmf4nqFXzo7zEfJmUGO+3uY9249HmHa8Gj8zOUMTZK+AByKrTmljazYZIq6bPYz7c7K2qHfdNRb9+sz3HruWt16HXbycFXOrEsAmjbZsY6x3u/GCWQLDrP9PQTZtHdtTean0LMY27rSzTrvMH/PZ6LDLoLHEZ7rQye6zbbkeEZvh0Cepe2aUCW40hXmvfNBbZTvyOpfrqc/Zd/GRilY+8J9+t+TPZ+vbdf7o/20ypxM/1l9ad77Of3ini7zfn2Ge8/dq19Z6+/JmXWPxJt5jd0YE8/tteynM7Bt2mefzkTvLOZjjvqv+xye032uMX3nuh4hju2SSrKmfc6QmIOj8T2/ZedJk6QvAue1wSyoRY7DqZvOc6bdWVkr2kyHvHW/HrQ2nefGw9rX2PpAveeTtX0whzlOkgJkM8wNP8fRT39y/TxiHXu9nzJ30GOn+xHmEH2sh/5+Rga955whKN1LhNY+7tXzByWsa7cjdlamfQVbuudZdE1Z/WsmVTBH9yuR9x1ZbeJ6+hN7W+PAxmmfvZ1DMHsi/e/JvrUv13vru9tP+k/9JnO8eb36rDnxuXBPl3l/Lw6sfeE+ukzMKzrhs+PNrfGOMObU4RbZf8aYJbGE34gNM+lyve7jYFw6m/PUgW3Uk+Vnnu1svyO29XNCXnQxl1Uv7affYMaco/HVndELTZK+CByfcykh93MTnWl3pg1H4ujTKa33DBy37jOG/nHeeRBrayN6rs8ce+e4kb3qZQOQ694Y5My+2qrXz4Exx7HZtVVHXxzN23PPcn+k+w5tEmRutQvGITP6pSRw+UnHCbn6HMEGZGQOOTzNwTj65hnZdD5CcNFG/9htB52MY30yB4UusQdZ6rSDcde5IX2/I2wy5+56ro+1iz+ybdYG8SHrFB+Z/Xeyz+7L9T5j6TP9wrU67SM36z/l8xP72b05KLknN/6Je7qs92QdxYG1Ldyr115feuNV8cbYuDfeijHS18/Y+Rax8dyndEL0i0zQRRvPduQ5uci8YwfzmLbPWDumXfRTJuQkLpJlnJmcec5mE8/VxVa78clRztAk6YsQx4tDwLW66Uhn2p1pYwNwpBxe8PzKvUDAAcmxYeaG1TYb3s8ZVMlQP4nsVS8On+BBRjZKmM/pks0Z6KV9NtZu3vpokw0aeeoy7hHmLPiwL5mR66f+s5Cb66zNDFxzvTL+7HOvRH/QeT6bgcL1DDQrdFK0mzJ2xfzXsZT42yzsbP3mPEPafEfiK8H19E824w9KbDjb57k149+eqcNOdnzLz1v7cr3Hup+CNY1ceiQW8En3EHuip/7ku+dnc764p8t6fysOrG3hXv074k3Gxr3xVrLW5M59xKb6HRXjzH1K95D4d7XkLIl9Z8n86bvb72HtlzJjT8ZB7Lsr7Jhr7XA0ftqdoUlS+RT4Dgd9NveCyDsRhBL8BDEIXjbvPWzkBFwycrB8BvNgXElQnwnvWaxNgtMKG5ifkgA6abx5Hrf23mftyyPygW1NJn4UXh1vzo6XD2e5tqeSrMykYse6T8lJ3Ho2R/v9Eci5GpueEW+aJJVPge88Ixg7tG16ju6nTxhHB/G7sSFn4MqnniRMRyQwSiQkS8+y3SMYd37KPEuSq3sB+ghzVsrHueU/7/CtvMHg38bmI4qD2Z5Rf2+PvIp3xxv2ObsP7LckN9m393TNPmV3sUa8emS/vwI6ptCVnutboazXVdj4rJ2bJJVPgWM/I/CRY3PwRZtbEHjkLccryKe77B263rKBzZ32rhMg10DwShwOdNgdXLtgpH2SwY/orb9SPs6tvfesfXkVvsNP7OGstX3N//nN7tP+O3h3vLE2dDhD4kVseavf3KfaJVaZ4zv84R70pV/iIz1dr2thLp5dXaPY7QxNkkopv8dM3lI++9N+400p5VVciTdNkkp5Ij7R+HRz9tNg+Xcab0q5jrdJfuW2e8tbjrkSb5oklfJEBKu8Gm6idJ7Gm1Ku4w2vWPPIr5y+M1fiTZOkUsrbabwppbyKK/GmSVIp5e003pRSXsWVeNMkqZTydhpvSimv4kq8aZJUSnk7jTcfwz/vfsYf75Lh71w+C/+0O995Y739dP/Mv6ehf/+QudziSrxpklRKeTuNN48jwfCHu8/4hwJXvszwKv4VFj0lMcaRyPgpUVKelSjRn9xSjrgSb5oklVLeTuPN1+CzkiQJEbm7RE5yJEnyNuwZGKdJ0ufiW9Qlu36y9fwONddzLZ+1rmehz/xi2934V+JNk6RSyttpvPkYbJf/osKvtBxgsal/Ij5//aTOQeKAy5udfON1kiSJi3rP1blXvyY5kpvURV7GnKxJkINUydsjumdc7N6MkZHDj6w5VvSHOjqbc/55vPtgjPQnk97h1rOVo/nSW1/Ppm2hrbnSJ89xpOtHoUvG+CiZV+abX5PSWck82UUbdtTHddb1FdDNmMY+Gl+dcoYmSaWUt9N48zHYLoerg8zB6ODNG5x58LrPAZ3DOQmMdp6rc9g5CLWFNupDZDscHUba5YsNk7AhMh1USg6xFP3Vu9YXxjWPIKHyPG8s6KatYh5TL+2S6Bg710FbfcjS37MkQ7eeTY7mm3p1ZJA150G36KvPquu09zNgV/qvScIRdKavMn1Gf3rFTybqzEMf7TI/62rsOf9XQO+MeTQ+fZUzNEkqpbydxpuPwXYOB4ez6/XtxTzw3M/DLgc7tPM8iUHuEdlJVMhwIMJBRM4ObTJekh+HKR3Ji66uo6cx3BsT+s1ECJExdYRr84nc3RymfWZic/Rs5Wi+6mdSRRaZmYdr80jS4v5I13dhXspMdGObOZeJ+ZiX+Wd9QY77e5h31v6jTBsejZ+5nKFJUinl7TTefAy2y0Gz2jHPwno/+6z91/skAQ5B9TlIV5kTSUASink9k5LImwewQ1dyhNkPeXsxS3B9dn5I3a1nK2m/squfdevz9d61uiM8n0nWGdgt7fWdSdkVrLX11z+J8iRvxuY60Vf7e8yEe0LWtM8Z4lc4Gt/zW3aeNEkqpbydxpuPwXYOhBxUORRzYMyDZr2fv5JQP9dhvXdoOXTUz8MnydOOOd68dmC7p+uqNzLG0Zxy0Dtc3QfXGQOu83zti8z/1rOVo/mqn0kCWWSSjVW39X7qeoRxzyY5eSNHp1mSfLLpmnS53iUsMK41Mc+pg/mpX5OwM/NBbB87BfKii7msemk/34oic6bD0fjqzuiFJkmllLfTePMx2M6B4IBz7SB1GDqw8iy4d0g6YNRroy3WQ2W9j3x9ZpLgWp32kZuDd8p36DnUjJ/kRluHbg7uMMeaB2GSJj/18XzqGJlhnYOxjO0wJWPqd/TMvWc5xI/mm3p1OdTNOay63dN1xRhpnzHvwXbmQA+yFXNB5jV1oLs2nu3I86xJ1ik2NOdck5uxdsSe0E+ZkBO/iG1mcuY5e0+SyMVWu/HJUc7QJKmU8nYabz4G2znU4WBwSDgUHXSezUPQvef5OZOdJCBhvYfDUd08rDATFmPnAJ+JgkNRG3We66M9mbsDP2PNwxT6q9c/h2dwHVtgnQO99aeHAzQHOo6esaO6Kfdovuypr2frvFbd7um6krWlT5IHzARoV8yLXrmfiYM5zrZnS9YkOs8S36Dv1HNl7ZdCv1zPtY8/7Ep8QtEOR+On3RmaJJVS3k7jzefBrmuSNO8/G4ecMWcychZ95oFe/h2JVxJP15KSJCtrQrli7ZNEgJyZqD0T65eE6aOQI0HcJdNHHI3PTsoZmiSVUt5O483nwa7vTJKQtxgOZweyg1yhh0/666d9b0q0cyg+klx9B9gmyQ07SiZn8rMjb8TYlM0lSF81CaVjCl3pufOTe0nhjivxpklSKeXtNN58Hg4Zh0lY71+Fwyy/ysp6O/jUrUmbeu3WQ7H8J2w27Whdj/A2Jb+q0i5votj4Hb5wD/rST6EzPV2vb5HMxbMrb5cQu52hSVIp5e003pRSXsWVeNMkqZTydhpvSrmOt0n59WU5z5V40ySplPJ2Gm9KuY5fVebXZld/5fSduRJvmiSVUt5O400p5VVciTdNkkopb6fxppTyKq7EmyZJpZS303hTnoVfQX2Vv9HxL8f8q7L+KuxrcSXeNEkqpbydxpvyLPjR+pUC7yLf9fSsL1Qsz+FKvGmSVEp5O4035Vnwo6+SJP0M+C6ifJnjxBs7b8q8JVu/o0n7vM2TKD66HvmWbX+cfut7oIIvLV3fIu6+YPNKvGmSVEp5O403r8chNw8Q1+qC+9Q9s90Oa5/D1KGYfvmywCkH6vOFk57NNzVkkXPUd+JQ1Uafta3Dn77qjaWtOm3XA/voyxzNafr1rfE+iuSAHs94a0VWvshRmUkPMi9zMG/X5obYSJFEaZNnj2AtzyRac9zoGt08m6TdGZoklVLeTuPN63FwzbcDObxzoOQAfHa7HdpJGBzMOYDXez9BBlkOQoewdnNcbfVTHKyz7yRytCFLIqBt0J9sY3iurTlKnDwLnum3S04yPu6N9wyMQd+z0CG2molEbH8rMWFzz41nHorxYw/XZLq+Jece5NPzTPKnHd3D6pMh+p6hSVIp5e003ryeHGYOsiQBioTCgeRZEoRnttvh2Tyo3Tvc5n0OWvUOvxDZxsStvpNVjjbaInOZB3OSnDzLXNY3ZpMp89Z478L8zEvJXNnNPOm2Sy6D+egXMp+1Xt3O/sEY2qRMH5m6kHuPNUmix65fxjpDk6RSyttpvHk9DiA2d0g5XJT8Skydw+kz2u3Qbx6kt+7XZ7j1fNcea71rdet1mHVJeOacd8w+fh6Nt0OyYJyjxHKHBC7t6UT+TMzOQoZkw5odje/5TIYg0V3XeU2aVjynZ/rOtklykixFl7RdddPes8DGqz4w3i3bT5oklVLeTuPNe3CgOEQdJA7YebDOT+TPbreizUwgbt2vh+7uTdItWYGOU45kTluQ5Xq+STIHY0M//cn18wjPI/PWeEdon3mdwRjkSiroSn91mYdnqzw6Tr0m1jNyVsiSCAfrq63CVsH9kfwQW6w2zzqkuCcrZfUpdcYL0/6TyDtDk6RSyttpvHkPSWjmQZ/7ebA9s51P/w6yeVhb+5nI3LrPGPrnjcd8e3DUdx3XwayfezLI1DZoq14/yd6cQ94gqZsJwTqGcSPz3ng7ps0i8xbaGyfJaQo96Gz8mdiALvrskLCYz7RvICf6sYF22tPT3IL6uR4rGYOe05Yr9Mwc5txSj9h73pO9kr5naJJUSnk7jTfvwYHG7vPgdK1uHsrPbOfAd4g6yIPnV+5zKJPjgM+hiKO+67gO5yQr5M2EBvO5sZIQBONqr11Yx/AzMu+Nt5KESzvtM0fX+h0V7Y1lnFkHMmfbjxbysCYuc/3NYdpoRV9FuyljLUnUdvNf+8ZuytQlpN0ZmiSVUt5O4015Nw7UV/rglfEkCEmSJCZJgtbEbYeEIcmMBEN5JbfGo5d5zCT3LOy3ewPGNuwlKWefXYJ2Jd40SSqlvJ3Gm/JqHNAOUoeon5KJo187fQZXkiR6Jdmgd9683Esu8hbPz92br3fDBuZxlSRXeTt5lSvxpklSKeXtNN6UV+MtgwOa3zlwJRGPvNF4FAf9mTdB0Da6KpKeW7pmboqkKMmSpOQrQTd6+TWkOU52CZD2SfZ2v0Y7S+x4hiZJpZS303hTyvdEMuTNWGKAskuansmVeNMkqZTydhpvSrmNpMEfgp99+1SOuRJvmiSVUt5O400pt5m/Qsu/niuPcSXeNEkqpbydxptSyqu4Em+aJJVS3k7jTSnlVVyJN3eTpJaWlpaWlpaWn62coUlSS0tLS0tLy7crZ+iv20opb6fxppTyKq7EmyZJpZS303hTSnkVV+JNk6RSyttpvCmlvIor8aZJUinl7TTelFJexZV40ySplPJ2Gm9KKa/iSrxpklRKeTuNN6WUV3El3jRJKqW8ncabUsqruBJvmiSVUt5O400p5VVciTdNkkopb6fxppTyKq7EmyZJpVzE/8D9p3/8J7/8+Z/92S//+Pf/8Ftt+QiNN6WUV3El3jRJKm/l7/7mb39NNiQdko9XY/z/8y//8tvdf6L+3/71X3+7+30kRv/tj/7rfyRKv/vd73578vkYi26T//5Xf/Xb1WPsZE6sy9m10W6126rfTt/Gm1LKq7gSb5oklbficOZnSTg+A0nNLhFzmMfP//Iv/uK32l9++ed/+udf6/z8avyPv/7rX3X7w//yB7/qz36uPwLbHNleAkn+2SRJ8qgkcZQQ0Zf8W/pmHUop5bO5Em+aJJWfHkmSg3n35sc9P59JQOq+4q/SksBJRGBe7o/eekFiZU7mv741W+WtJCk7kyTNpNNYSH/yk3C5X/VNv1JK+WyuxJsmSeXteLtw9OseicrZtxiP4A3S+mZDHd+/92s0icezdSMve0+RZEwkGupjryR/t9BWkqLd+quuyFvHCVeSJORNkT7ss+p3pK/2SimlfDZX4k2TpPJyJCE5lPMmQ3F4rolJDvcdSSgcxusbkrMkCZjj5ldEt2TmbdNRcrfDvO8lXuZK7iyzj2t1sR/7rEleuKW/OXqetz/z142TW0kSXZIIrWMl0aTffGt0pK+2Sinl50asWOPCFfKhT7y4FX8Tx3dtrsSbJknlpThYHbySAZsk1/NvVyY5bNdD2kZLopLi/tYbD8/XjZkkYNanbpdk5Fd30WvVFzbl+qs6ddqnnp7GmRgvclN2CWLGh+e7pIP8I1vQgWw6JemKPNArfWOLnSxzN/ZOz6yN59O2R/pqq5RSfm7EEnFgJi8z5kzEpcQP8VE/sUX7W4lS4pZYo8wPmrgSb5oklbfC0Tk0bIg4dBIUP/nheggHz3MgzzIPfSQxOEpe5h9ppy46BJtVfTZpNuAkbY5+rZUNfZQsIBt8pwP0i/wkKiuerzaYTBmu05b+7mPv6LIGMO21sVbThu7pZF3dJ6iFI30z31LK9yIxZ8YJJK6I2Yk3Mx6m3xpr9VOv7Rp3w5V40ySpvBybYR7Q8TXFs2yOZxSba1e/FnokEcj466ePR/Rax88mz+Z9tCTZS/BYOTPvyDD3JKqY858J21GxZn6Sx4a75+FI37QtpfzciBE+RM2EZ8bWszH7TBF7dolUnp+hSVJ5KXnzwHl9EsgBm+KgXZMRGyqvVndlbrj1kJ4b7khGEjXPo59+K3STNCj0Pkog5jhz/Jkc5FNQnq1ltcss+gXy6bvCHrfk0zFoNwOWeWaMdS1Ssoa5j7xd+/kW6kjftC2l/NyINWLHjANiTmJAYqYYdBSzbxVyJUWzbsY3pP4MTZJK+X+xaW1UONQlMZ+FDSthmonKo+wSjquswUpwWj95HcFW03b37Hakb+NNKd+TxJzdB9OPIBaRuYtlV+JNk6RSnoRNKflJmQlDPh3NksTiK3Dvk9cZzFfidzbBmmTcUsr3YMYcSdK9D1jP5Eq8aZJUyhPJr+IkC/PXTBIiiZM3KfaVdl+NJHJT7yuY9/p3XGdpvCnl+/HRmPMoV+JNk6RSylNIwJMMXqXxppTyKq7EmyZJpZSn4C1Z3ySVUr46V+JNk6RSyttpvCmlvIor8aZJUinl7TTelFJexZV40ySplPJ2Gm9KKa/iSrxpklRKeTuNN6WUV3El3jRJKqW8ncabUsqruBJvmiR9MXyfDrv759STW/f+RZF/dv3ovyy6gu/CmV80aExfBEbn+Q3S9Es7/+rpzL980p78d+G7i8zhnp7rWjwKOfM/1g2x18qRfW6t/9EYn4UvhOuXSZavhJi67id7/ZlfXmiMR/z+UdbxPjIf31H0Wbqven40dopl5InTH1m/K/GmSdIXIgkHJ2D7HHqc2H2+cMth6Z4Dws/5/LNwQK/fgSP4GHsmTpzXPDxTb2Mo95x6nfcrodu06RGr7R8l4+2+VFIA2H3X0JF9jtb/1hiPYFx6zbknYCVJc/9IoktPpZRnwzf5VhIlB+1uv6zYN/oq92LXOsZnM8f76HzU62/vJgk5IjFAudUuTD0V11fjO12dH/pGz4/G38g6Q5OkLwQnz9sYSUYSD07lPll4nHo6uufPOgx3ZIOtDu6eLmtwmE6t6HuPJCCfneztsPHO6KgdHZ/xxouNdmMeBZNb9jla/6MxHkUQnQGKD7o3tmv2aZJUvhL80/7IfrJ/+NqMnzu019d+TCw+QrvE7lcwx/vofNSlP1n27y1ZYoB2Z86bqaf2t2xEr90Zk3h4bw2uQJ5yhiZJb4R9OVHIJ4KUeRjOg9OGX7N4h+Gtw2mVvSvGOCLJwdQ3cPx1w5BFzx102W0G6LPTw9x2Y2u72gK3xlgREMxNn1ukHV3W9sYx3m4j39KdnJUkQzt9juxztP5HY3wWR0nSPf+k4yv1LN8He2/6ln3l/l5SAXtxt99W1jFA/i42PYM53kfnk/6fwdTTuPcSyXzYmiTe3oofVyHv7JybJL0R9t0dnnDgTme+dUCDcz3TiXbQaefkxl2Dwa2N58A8mvs6byRp2I0tafBs3Vi3xlih/xnb0YvMXaKaZ6sdbumeT4Ar5Ktf1xg7++Bo/Y/GmCTBi63ovIONzWOnW3TaJUnRQdF/Jz/Py/eFH2bf+nkFfqcfP15jQWIR+UgsPfLzEH8/Ext28c6eECcy7lXOzAkfnU9ilOeujef+aN4ZW7k3t6mn+MIeV5l+scbXW8R+u3gZ/c/QJOkNxLazrIc5p1idNIu+c16OcGYzP0oOut1GpNfqiDbH0YbQ1kbcYQ6rLGOqX21k8xh7t3FujTHJJvbzFsYynwRvSYl+CV7sswtmR7pjBpCVI5129oG63frfGmOiHR3pv5MP8j1fdXBtDHO1FlMPdhOY9WM/17uDQ/8zepafF3tr3Sd8a/VHvpo613yK3+V63Qf8km9lb/rpXvsj6GKP02eNY/qvsWUdA4kZO/0TR8JH5vSM+ehvPPPShi7qVt21jS6e0yPs5jX1JNf1LbTRdkdi7tSJ/NU20EbJ3FaZ6u7pEpokvRH25RQ7kpRMx4/D7frEKT4DDrbb7CGbebLbMGfg8Lc2+7Mx3hk9sx5+ImvxEZub526DY5dI4Mg+R+t/a4wJnzKen7v2ZJuvIOrnGnToyyZrkmT8zEWwjy99JGiVn4f4LL+z/qt/8yd+M9HGnlXWDybxt4nnZGfv5n71wZC9To4xXPPtYIy1jqz4+dTf/FIfUjd5ZE6R+9H5JJZJQiZsr/0k/em4rstuXlNPa7z2mWiz02PCTlP/+M2ce+YTXzKmdhPPlTM0SXoj7Lsu3oQjzs2F1WkDB13bPguy4w/K6sSer9iYM1icZSfrs9htsFvsAsZHYJ8jGx3Z4Vb9bv1vjRH042uCYoLaXO8zJcGPjN3zWXZ2y7PyfeB38Wc+yofiB9NnH/FHJQfqLMbj47cOa23sh/Q5O378ejeuMuf3aJmyM95nzeeorP1389rpKd6KD7ew7lPOrpA9IX8+p98ah5Igh9SfoUlSKeXtNN58PxyI6wcu9/PAd7g54J+Bw1XC4E3DrQ+nPxo/ynySoN5Cm1tvklbyoW73AdEzCVSStMmVeNMkqZTydhpvvh8SIAlRDk4HJB9Q701A3gZ8tQSAPkm2HkFf5bPe/L+LR+fFjtY6b4TuJVIwjj78x8+rXIk3TZJKKW+n8eZ7Mn8t4zqJh0RE3SMH4GeSX00rt37FdYT56af/V5vbR/jovPSx3mcTYuN5g2S8R5LN+NwZmiSVUt5O4833xVsBb4/OvEEo5RlciTdNkkopb6fx5nsiMcqbGaWUV3Al3jRJKqW8ncabUsqruBJvmiSVUt5O400p5VVciTdNkkopb6fxppTyKq7EmyZJpZS303hTSnkVV+JNk6Rvij+Y9M8u/bNN65zvm/js7+7wBXLrN6aW0nhTSnkVV+JNk6RviH9u6zsmJCu+l0Li4qdESfnMRCnff1LKpPHm58IHrvyLtc/+4FXKVa7EmyZJ34z83zi+m2RFMJMk7b7G/Vk0SfocfJW/pNdPX7Q2v5TNus7DSptXficNXeYXzH30vwn42VjXJ7BTvlzxzLcZaxvbsrk13u3zq/hQNf3pDBlbeaWvfRT2zf9NJha+ivmlmtNe7Jf6e2sQPwIZ2p9df+3XN/z86au/9af3jC1niU3P0CTpByQbxmGXN0IcWv26KWz0WbcmQfopCb4CIjkzGM86YxnT+Ot9UG8M9cab/xePdpHFuaP/EZmjPmtb8yI/9TYMuWfsEKKnPgLMDFAJEp7pzw4fhQ635nuFzD+659el5qQu+mb9Mof57BXQzZj0VVzTc6JO+Y5kT8w14Yf8kr34oTVVpn+uZK/EB8g9e4BkPGtlzAnd5v6+ytz/X534J5u/CmMZc7U7rIm13GGt5rPsbR+EyVJmrMnzdW7WXmxY14nvaL/u1VdBT3pNfemkztzp5f6ReGpeyhmaJP2AWBebh3PYENksiuuQt0YJrDNBUbTNOqedetf6hvQzno3EMRNQ531Qry3nJsezbMApi763Dm2bXF99yMmmnc/UG4c8mwf37DChl+cKGenHDuQbU791jo9CrjH9PEPWSaFDiH4zSAa2MV+FbdyzjTnG3jtbfBbWL2tj7rmeRN/virXMHgnWNnZRpk/vsNazvbLbV0dYJ+39nJCz1p0le2/67lfGvqKvPfNKrO1uL/OJXdzJnvKMjYP7rL0yfUp744hzkzW2hPjTFR96NtZhzk/cMnfzSlxe53OG2OcMTZJ+QKzL3FAzYfCMc0Ob6UCu049z2TSCAmfTLwen6xkUXatL4Mh9NmDuER3mIRz9kLZzU7qf4wX6zU0+x1mfZQ7Gv2eHldhgyndNZ/VK7PUOzIcNY39kjpnzjug8bZF+c312ZM7PYNrVHHZ2zFy+KzsfnftmxTo63PjuRPvpJ1ex5qtM67Lbn2cwJ/v0XXvniFv7YI0tgV2ftSdWyN0lwdk765poK3nRb+rKjxLjJ9rqY75Tnp/q+U1ixOTIn6zrzic+00Y7jLWL7fdiPhsoZ2iS9ANiXaaDzkMoG5zzq5ufAqbDz+sZMNJvHrxTPm7dr89w77l79Str/ey76zPrbtlhYjN5Pgv0nXUCybRJMJ5nCTpnYPe0zziPfFrTxzyPAlzmPoNmguSu/YSO5K7zYoOrQTD+BfYid8XztPmO8IM1qE+7rcRv1z1ARvb1Lazhuo76kbn6+ToOn+Dz4E/Wc7cHIs/P3d55J7HtLkliw52Pm+dRn4/CRrtEcqenvZs9pN/U1f1R0uAZ9J3yEid2c7au6ReMr/1O3zM20l/fxKCjWJS5k7nzLdB5na+4qF903MnP8zM0SfoBsS4zaAmwcVjOw6l2h9HsN69tBPccMQ42nVI7deHW/W5TT/3WvnAfXSb0nxs0BwPIm8+M51mC8S07hFVXmy3y0/8M5ncrKEwSYMg3vjH9jH3YfXfgCAa7zW5ceuo/dXBNTtY2SZj6aacjjL/aH0nqQJ81QGXcSebs2W79oW5X/11g59WW1ujIB7Vf7Qwy1jXbYS2sJYxjb8UP1/7WZe7PxAjt47/ruOSTGf/b+dI7oGt8bRb6Bntt1dV+UL9LJFZ28u/NnX3X9Qe99J+Qxba5zjpiPpuwf+KH6xlfEp/XmIOdP2XfrzH7io3ItBZk+Lli3rGH+c/Yp2/qjDXtRofEQvN0vc4XWZczNEn6AbEunCNONgMQZ/Bc3dw8mO0EL5spTqYPWZxqdXL10xfu3ZNBJicWUOe4a1tkbO31zaZJkHVPHjnpa27uPcumnYfGzg6r/AR7P815yk9wip1TVoxDd/i5bsYd5sUe9DJGijGjY2SCzGnDFXrpP4MjWyR46JdnmZefO+Yc9TPunFP0Q9Zyyoou2gXPI0ef9J/oo3xX2HpdX7aca3qG7Lt7aJN2SWT0tTbrmJ5Nf4T11D/rlrLGHJjXbLPO8x3ET3f7IHv+lbDvzi70yz4Oqz3nenu2k5PYpsz1TQw88hljf4YtoiNb7/SlI7345i5exP/0n/aha2KNfok96zrHFmdokvQDYl3i9H6ugSkOtjoGZ0oiEWdSx6E4mz76zkMR2Ujh3n02NvkcdW6CtS3cq+f0+rjGlGOOOZSDOvI93+m92mGVD/K1Mf9VPhuRr87P9aCAOjKzYUMOnqNCp9hi1oG9Zv3ZkmDGDuuz6G4Mczki9lhL7KDM9YyN7xXtQI9pp5B23xU23e27qwfULknZYQ2safw29ufLub5V+Anu+blinOg19947YVe6Zc9Ndof2Z7Nbf9Dzig8cyTli7l9rv8a4z7AFn0s8XWPg2ZIYNn33qCT2TPLsDE2SfkCsy+rMZ0hgeEcQeAbm/FV9UmBKAup6JkH3gpy2AlQg57MOEwHqEd/ZEb2vBGW+tzuY2Omrrm25j8PqR40r5ftxJd40SfoBsS6PHnQ+0ekvu84nVYU8gU75KjjQ6eZQ9dOnh92ngq+ChCHJDXue0TfJlb5s7zqfkr4a1sBBqNCVnqu/mM8jh2XjzY+BvRgfCHz9arJcyju5Em+aJP2ACFASiEdx2OXXWFlnB566Z71leAbmSS/60VXC8ZUDMdtNe95LFpKwsvtMlj6ytp8J+9Mxc3S9rkeS2atvwiKzfG2yJ/mpNY4/fKW4Uco9rsSbJkmllLfTeFNKeRVX4k2TpFKeiE/U+TVmOU/jTSnlVVyJN02SSnkifnWWX5v1bzTO03hTSnkVV+JNk6RSyttpvCmlvIor8aZJUinl7TTelEfxxra/3i5XuBJvmiSVT8WvnxrAyj0ab/4T/8w+X5TKJn51+9F95O/kyHs3nxEP8q9Kb2FMY5eCK/GmSVL5VPhQ/3lwucePHm8cwFe/9mCHw1xS5O/a7Bv35Po+KvY5+43aK2cSiVfwGfFgN7d1Pb7K/MvXgC+c9YcmSeVT4UPPDorfHQenQ9NhOr+92sGQ71jyfTbzD8etQb63yeHxkTVxgCtnPpnPccPuCzZ/9HjzDD+3ruQcJULWzXPtrkK3r2DfZ9hpZTe3dZyvMv+fBT5q//vJtvO73VzPPX7vC3WfDX3ml9x+NN40SfoicLjVseYh5D51z2y3kkDsgNXeQczp3OdgnnIwv2DOs3lwk6W/Nru+ExtOG33Wtsanr3pjaatO2/UQ9nytQ/pHPr0mGV9Zv0n6EdiBLo8caitk0Z/uCtvMOWbd6C5IuZbIBNfqsg7m+ijkG4+smYjtmOPCT/drP3XKPbSxblkrdsh8pz1w5AdsqZ8+ZMw2Rz6gbeaccZHEZhbtcEsWOWxDx+B67kl6kj/3kz7rvj0aJ/XGy8/Ahlkbz9a9MMmctNE2c19tEdSbS55N/ckix7yMv45tLbM2ZMSWt/R1rR5H65E2t+LYZLXdbPuMWHQ0z+mbijknfqi/pfMOY1/tc0TWNXqxo3mzg5J1Zg9t2Egf1+t+/0ziJ8Y+Gl+dcoYmSV8EjsUBQzZoFte9BX92u5UEExuLjBlQOL3N7Hk2NRme28jZ+HNcbTmtEtnpO4kcbcgyrrZBf7KN4bm29KOTZyFBcgbmoL2xtTGeduTBePT2LDL8/Cjms5vvEfSIvebGjn12axbobzz9XJsD+7jXN9fqtXsUMuh5xj7GMXbmsvploJNyD23I4wvGZyfzuuIHxk//FNzyAddZF3Nyn3U1hntrk/HuyTIHbSIjMtlJoZ/7FG0RPwhH46Qdue618ywYN8+09Sx7YcUz+pi7frv7zCPjknsUD6xVdMs1zNs1XdnRzzy7pW9sF3brkTb0Meaq9+Se7cybnEdj0a15rr6pPz0Q3a9gLLr5eQZzooOScRGdd+Oro6c+2tGTHcztaL9/JvTOmB+NN2iS9EXIhuBk2XiKTZxNn035zHYrCSYCxby3kYP7bCAOyBFDZBsTrrN5cj83X1jlZFxkLmSHGYw9y1xsWJv0CHpETnRRl2vPIjNzeCXGN7cZ4GFOdJo2WmHDrBvYhI3Uz+CWuR6RAyRl9ZPookwdd8x1BP3osxJ599BmzuWqH+x8Cfd8wLXAf+TH8/6MrFU395mXvcZG0XGu67TnrXH0OdpPE/2mnB2erXMnf2eLdVzyPZ9zt16Z29TLdZ4pscNkp++UEeZzpM1RHJvcsl1sHP1x1QfJ281zJ/tIx8/EfJSZQEY3JWs5sSZ8xDyU+AY56xruMMdnzXOu19H4mcsZmiR9EbLxOaZNo9hkijqb6jParUwHw3oP93HoeR1uPd+1x1rvWt16HWadTSCozTnvYAPPZyFHUJp1bGNzrQh+xlqThluQnXnRi/xbic4R5mbtovMOAXnV21j6TJ3NYTe/4Lk+gt5qC3I8M685XtqutklwpT/ovvM9bZR7aDPn7zr9zvjBbD+55wPq5ri37q/Kwmyztp/3frrHrXHWMVyrC4kBs/+qU1if3brfybn13LU6xFdT+FQO5Fv6ThlhPseZNuFW352cWXfGB4/muZPtfuryCHwi+y/7lO9cxVzMT/9dDPScvtN36a79PcS2XUJJ1tX5J+bgaHzPV1sf0STpC8GBbSCLaqHjdOqmAz273WTdqOs93Mdx1wM3gdt4mG2x3gc6TjlJCBCnnxvbHIwN/fQn188dkZHNHVvocyugrRgrczuDedDJGPQ1B/eZC3lz3qDTWhfMm647HYwlEQxkaMsPlLCu2Y7YX5l2Nw/651n0T1n9aiZVMDf3K5F3D22m/zzqB3NOuOcD67i37q/Kwqyb11lvcwP7WhvcGsf80wdzP8FzsjH3wo712a37q/HAtTpk/Xbc0nfKCLfGCWubcMt2O/+56oNH88y8rCsy1k7Hs2T/GXOWxAljiQ0ZE66PzgfzpntiWaCrerL8zLOd3XdkrvGTQF50MZdVL+2zH8KMOUfjqzujF5okfSFsNg42N1DuOXZ4ZjsOxeHjnKtT7ZzMfTZuxtA/TjwP5NkWuV/H5ej6uSeDzDmutur1E0zmHHJYqKNPmGMkAPmpn/qpG9lpq0ydJ9Nu0f0W2tEr46dEvmBl3Ald1o0/iX1mkAJZ0S/j0ZF9tKcLjHc0P5Ab+0x7rhjLONZtzo1+CbpkqdMOxl3ni/S9hzbmmTW66gdwTUf3SnS75QPk3ro3ZvQy3hVZmPNgT+vvngwl9/pmHXE0zr39FH211z86rbbCqu+t+6vxwLU6xFdixxQc6YvV15H20WOOEyJjnfOzY9Eq/2ie6asfeRk38zTmjAvqM99bxHfmPqUPolvGAF208WxHnkeX6B0b0DPX5GasHWQF/ZQJOewEsowz417sNPFcHb2OxidHOUOTpC9EnC9OAdfqpjM9s52NwKFyUCTghPUe7tMeNjVHJMfGmRt3bZv7dVyObYOoIy8bIsznxsomDMbVfm6gdYy0IUe7qRud81yfdbNiBhQ6Zp6u9TsqbJ6Nmzoywqz/aElgW3WagcL1tNOKYKpoN2XsChvs5h8/m8Wamff0x5A299Am9vLT2JMzfuBZDowp45YPqEt/rPfmFb1cX5EFz+kEe1Mf93TV1r31WPsdjaOfa3XmRydtQvQ1BvtEp9VWWPW9d288upJDt+wTrG1dqwvmHr/zk5440hfkZz1Tl/bqXK/jIO13/nHLdvM5He/Fop1Nr8wzz9RlfTH3UeZ/VOhiLrk3ZqD/bHu25AyJbWfJ3Om+2+9h7ZcS2ygZB7HtrrBNrrXD0fhpd4YmSeVLwrm/sv8JSgn+gpmgILitAXOHAKAPBBiyXkmSgh0J6PNgO4s1S3BaEcDYRkkAnZyNN9rk0PiZcBCY2xn/Ka/lnbHIuDO5CkkMc21PJVmZScWOdZ+SsxvjGRzt90dIjL0Smz4ab9AkqXwJHM42N4f2UyJxdOB+BeiWZIPuAg2d721gn2q081Oxx77SoU8X+l0lydW9AH3E2Xjz1ez1TPJJX0JpjmypOMAEe/VJrsvn8c5YZK2Nr4gPt5ICz5LcZN/e0zP7lD+Rn7j1FaFjyoybk6zVVc7GGzRJKl8CG8Em4HM2sc1+5RPDq7E5o69i897SN/NTBF9BLf2+EnSj1+5A3gUj7a3VR+cSO96DHVe9fibYmD3tgdiEzzjM2Je9y+fyzlhknbP2rm8lAIkh8RF6HzH3qXbmk7G+4n6iL/2UrIPrdR3MxbOr6xO7naFJUinl9xCYE5xSPvstRuNNKeVVXIk3TZJKeRBJQ34VUj5G400p1/E2SQx65FdO35kr8aZJUikPktfySv42oDxG400p1/GGN782e9WvBH8GrsSbJkmllLfTeFNKeRVX4k2TpFLK22m8KaW8iivxpklSKeXtNN6UUl7FlXjTJKmU8nYab0opr+JKvGmSVMoXxfea7P7Vij/QPPudRPk+FPjuEf8a5iv+a7zGm1LKq7gSb5oklfIFkdDYf7v/QkSS49nuiwUlRJKr4F/daSvZ0k/xL2K+Go03pZRXcSXeNEkq5Ysi2clboEm+DXh9I5T/msA/B55voNxnPyu3/u+2dxHdSinls7kSb5oklfJFyRujSf4rAm+D1u9GkVB5c+RXcTMRkmzNt0tfkcabUsqruBJvmiSV8sl4q5O/IZLUSG7Wt0A78quySb48zrd9eyZpgntyQfb8m6VHfsVm7N2X0+X/VLoKHfJGKzpPGm9KKa/iSrxpklTKJ5P/3R2SDG913N/7v9AkV3MP5j4JlmTFr9egLm+LXM83SfPZWY7a503W/HXeivGiY5IqSZo+rvVf/55K3ZxrKaV8FlfiTZOkUj5AkoFbSIaSzARvVc4kSfMNUJKtvOExtntycp0yZc+k5Sy3/quVqUOY8umZt2XkzIQqb9LWuUfvUkr5bK7EmyZJpTyIJCKJRH41NosEJ9dJVHK/Jk07JBdrgjF/jbbeH2HcNanZkaTGW56p61qSuHnb5FrCM3+FZqxdv5Td3POslFI+myvxpklSKQ/ijUmSpLwZya+WvhMSqvXvjCRCZxKz0HhTSnkVV+JNk6RSHkRykD9ilhAc/a3R2Tc5XxW6m8MRksUkhvmbq6uJYuNNKeVVXIk3TZJKeRDJQ/4QWZEcrAlS/nD5zK/FvireEnkzdPQ3Splj7GCuV5PC9C2llM/mSrxpklRKeTuNN6WUV3El3jRJKuUD5FdRt34dVe7TeFNKeRVX4k2TpFI+gH995p+0+3VTE6XHabwppbyKK/GmSVIp5e003pRSXsWVeNMkqZTydhpvSimv4kq8uZsktbS0tLS0tLT8bOUMTZJaWlpaWlpavl05w2GSVEoppZTynWmSVEoppZSyoUlSKaWUUsqGJkmllFJKKRuaJJVSSimlbGiSVEoppZSyoUlSKaWUUsqGJkmllFJKKRuaJJVSSiml/F/88sv/H5yhQtYK40I4AAAAAElFTkSuQmCC" /></p><p><img alt="" src="data:image/png;base64,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" /></p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL" style="text-align:right">احفظ هذا الدواء بعيداً عن نظر و متناول الأطفال.</p><p dir="RTL" style="text-align:right">لا تتناول هذا الدواء بعد تاريخ انتهاء الصلاحية المذكور على الكرتونه بعد &ldquo;EXP&rdquo;. تاريخ انتهاء الصلاحية يشير لآخر يوم في ذلك الشهر.</p><p dir="RTL" style="text-align:right">يحفظ في درجة حرارة لا تزيد عن 25 درجة مئوية. يحفظ في مكان جاف.</p><p dir="RTL" style="text-align:right">لا يجب التخلص من أي أدوية عن طريق الصرف الصحي أو النفايات المنزلية. اسأل الصيدلي كيف التخلص من الأدوية التي لم تعد في حاجة إليها. هذه الإجراءات سوف تساعد على حماية البيئة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL" style="text-align:right">المادة الفعالة هي فاردينافيل. يحتوي كل قرص على 5 ميليغرام فاردينافيل (كهيدروكلوريد).</p><p dir="RTL" style="text-align:right">المكونات الأخرى للأقراص هي:</p><p dir="RTL" style="text-align:right"><br /><strong>لب القرص</strong><u>:</u> كروسبوفيدون، ستيارات المغنيزيوم، سليولوز دقيق البلورات، سيليكا غروانية لا مائية،</p><p dir="RTL" style="text-align:right"><br /><strong>الكسوة الغشائية:</strong> ماكروجول 400، هيبروميلوز، ثنائي أكسيد التيتانيوم (E171)، أكسيد الحديديك</p><p dir="RTL" style="text-align:right">الأصفر (E172)، أكسيد الحديديك الأحمر&nbsp; (E172)</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL" style="text-align:right"><strong>ماذا تشبه أقراص ليفيترا وما هي محتويات العبوة</strong></p><p dir="RTL" style="text-align:right">أقراص ليفيترا 5 ميليغرام ذات كسوة غشائية لها لون برتقالي و على أحد جوانبها علامة BAYER و على الجانب الآخر مقدار (5). الأقراص متوفرة داخل شرائط في عبوات تحتوي على 2، 4، 8، 12 أو 20 قرص. ليست كل أحجام العبوات يمكن تسويقها.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL" style="text-align:right">باير ايه جي.</p><p dir="RTL" style="text-align:right">51368 ليفركوزن، ألمانيا.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            مارس 2020.
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Levitra 5 mg film-coated tablets
Levitra10 mg film-coated tablets
Levitra 20 mg film-coated tablets

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Each tablet of 5 mg film-coated tablets contains 5 mg of vardenafil (as hydrochloride).
Each tablet of 10 mg film-coated tablets contains 10 mg of vardenafil (as hydrochloride).
Each tablet of 20 mg film-coated tablets contains 20 mg of vardenafil (as hydrochloride).

For the full list of excipients, see section 6.1.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Film-coated tablet.

Levitra 5 mg film-coated tablets
Orange round tablets marked with the BAYER-cross on one side and “5” on the other side.

Levitra 10 mg film-coated tablets
Orange round tablets marked with the BAYER-cross on one side and “10” on the other side.

Levitra 20 mg film-coated tablets
Orange round tablets marked with the BAYER-cross on one side and “20” on the other side.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Treatment of erectile dysfunction in adult men. Erectile dysfunction is the inability to achieve or maintain a penile erection sufficient for satisfactory sexual performance.</p><p>&nbsp;</p><p>In order for Levitra to be effective, sexual stimulation is required.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Posology</u></p><p><em>Use in adult men</em></p><p>The recommended dose is 10&nbsp;mg taken as needed approximately 25 to 60 minutes before sexual activity. Based on efficacy and tolerability the dose may be increased to 20&nbsp;mg or decreased to 5&nbsp;mg. The maximum recommended dose is 20&nbsp;mg. The maximum recommended dosing frequency is once per day. Levitra can be taken with or without food. The onset of activity may be delayed if taken with a high fat meal (see section 5.2).</p><p><em>&nbsp;</em></p><p><em>Special populations</em></p><p><em><u>Elderly (&gt;65 years old)</u></em></p><p>Dose adjustments are not required in elderly patients. However, an increase to a maximum 20 mg dose should be carefully considered depending on the individual tolerability (see sections 4.4 and 4.8).</p><p><u>&nbsp;</u></p><p><em><u>Hepatic impairment</u></em></p><p>A starting dose of 5&nbsp;mg should be considered in patients with mild and moderate hepatic impairment (Child‑Pugh A‑B). Based on tolerability and efficacy, the dose may subsequently be increased.</p><p>The maximum dose recommended in patients with moderate hepatic impairment (Child‑Pugh B) is 10&nbsp;mg (see sections 4.3 and 5.2).</p><p>&nbsp;</p><p><em><u>Renal impairment</u></em></p><p>No dose adjustment is required in patients with mild to moderate renal impairment.</p><p>In patients with severe renal impairment (creatinine clearance &lt;30&nbsp;ml/min), a starting dose of 5&nbsp;mg should be considered. Based on tolerability and efficacy the dose may be increased to 10&nbsp;mg and 20&nbsp;mg.</p><p>&nbsp;</p><p><em><u>Paediatric population</u></em></p><p>Levitra is not indicated for individuals below 18 years of age. There is no relevant indication for use of Levitra in children.</p><p>&nbsp;</p><p><em>Use in patients using other medicinal products</em></p><p><em><u>Concomitant use of CYP3A4 inhibitors</u></em></p><p>When used in combination with the CYP3A4 inhibitors such as erythromycin or clarithromycin, the dose of vardenafil should not exceed 5&nbsp;mg (see section 4.5).</p><p>&nbsp;</p><p><u>Method of administration</u></p><p>For oral use.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Hypersensitivity to the active substance or to any of the excipients listed in section 6.1.

The co-administration of vardenafil with nitrates or nitric oxide donors (such as amyl nitrite) in any form is contraindicated (see sections 4.5 and 5.1).

Levitra is contraindicated in patients who have loss of vision in one eye because of non-arteritic anterior ischemic optic neuropathy (NAION), regardless of whether this episode was in connection or not with previous phosphodiesterase 5 (PDE5) inhibitor exposure (see section 4.4).

Medicinal products for the treatment of erectile dysfunction should generally not be used in men for whom sexual activity is inadvisable (e.g. patients with severe cardiovascular disorders such as unstable angina or severe cardiac failure [New York Heart Association III or IV]).

The safety of vardenafil has not been studied in the following sub-groups of patients and its use is therefore contraindicated until further information is available:
-	severe hepatic impairment (Child Pugh C),
-	end stage renal disease requiring dialysis,
-	hypotension (blood pressure <90/50 mmHg),
-	recent history of stroke or myocardial infarction (within the last 6 months),
-	unstable angina and known hereditary retinal degenerative disorders such as retinitis pigmentosa.

Concomitant use of vardenafil with the potent CYP3A4 inhibitors ketoconazole and itraconazole (oral form) is contraindicated in men older than 75 years.

Concomitant use of vardenafil with HIV protease inhibitors such as ritonavir and indinavir is contraindicated, as they are very potent inhibitors of CYP3A4 (see section 4.5).

The co-administration of PDE5 inhibitors, including vardenafil, with guanylate cyclase stimulators, such as riociguat, is contraindicated as it may potentially lead to symptomatic hypotension (see section 4.5).
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>A medical history and physical examination should be undertaken to diagnose erectile dysfunction and determine potential underlying causes, before pharmacological treatment is considered.</p><p>&nbsp;</p><p>Prior to initiating any treatment for erectile dysfunction, physicians should consider the cardiovascular status of their patients, since there is a degree of cardiac risk associated with sexual activity (see section 4.3). Vardenafil has vasodilator properties, resulting in mild and transient decreases in blood pressure (see section 5.1). Patients with left ventricular outflow obstruction, e.g., aortic stenosis and idiopathic hypertrophic subaortic stenosis, can be sensitive to the action of vasodilators including Type 5 phosphodiesterase inhibitors.</p><p>&nbsp;</p><p style="text-align:justify">Serious cardiovascular events including sudden death, tachycardia, myocardial infarction, ventricular tachy-arrythmia, angina pectoris, and cerebrovascular disorders (including transient ischaemic attack and cerebral haemorrhage), have been reported in temporal association with vardenafil. Most of the patients in whom these events have been reported had pre-existing cardiovascular risk factors. However, it is not possible to definitively determine whether these events are related directly to these risk factors, to vardenafil, to sexual activity, or to a combination of these or other factors.</p><p>&nbsp;</p><p>Medicinal products for the treatment of erectile dysfunction should be used with caution in patients with anatomical deformation of the penis (such as angulation, cavernosal fibrosis or Peyronie&rsquo;s disease), or in patients who have conditions which may predispose them to priapism (such as sickle cell anaemia, multiple myeloma or leukaemia).</p><p>&nbsp;</p><p>The safety and efficacy of combinations of Levitra film-coated tablets with Levitra orodispersible tablets or other treatments for erectile dysfunction have not been studied. Therefore, the use of such combinations is not recommended.</p><p>&nbsp;</p><p>Tolerability of the maximum dose of 20 mg may be lower in elderly patients (&ge;65 years old) (see sections 4.2 and 4.8).</p><p>&nbsp;</p><p><em>Concomitant use of alpha-blockers</em></p><p>The concomitant use of alpha-blockers and vardenafil may lead to symptomatic hypotension in some patients because both are vasodilators. Concomitant treatment with vardenafil should only be initiated if the patient has been stabilised on his alpha-blocker therapy. In those patients who are stable on alpha-blocker therapy, vardenafil should be initiated at the lowest recommended starting dose of 5&nbsp;mg film-coated tablets. Vardenafil may be administered at any time with tamsulosin or with alfuzosin. With other alpha-blockers a time separation of dosing should be considered when vardenafil is prescribed concomitantly (see section 4.5). In those patients already taking an optimized dose of vardenafil, alpha-blocker therapy should be initiated at the lowest dose. Stepwise increase in alpha-blocker dose may be associated with further lowering of blood pressure in patients taking vardenafil.</p><p>&nbsp;</p><p><em>Concomitant use of CYP3A4 inhibitors </em></p><p>Concomitant use of vardenafil with potent CYP3A4 inhibitors such as itraconazole and ketoconazole (oral form) should be avoided as very high plasma concentrations of vardenafil are reached if the medicinal products are combined (see sections 4.5 and 4.3).</p><p>&nbsp;</p><p>Vardenafil dose adjustment might be necessary if moderate CYP3A4 inhibitors such as erythromycin and clarithromycin, are given concomitantly (see sections 4.5 and 4.2).</p><p>&nbsp;</p><p>Concomitant intake of grapefruit or grapefruit juice is expected to increase the plasma concentrations of vardenafil. The combination should be avoided (see section 4.5).</p><p>&nbsp;</p><p><em>Effect on QTc interval</em></p><p>Single oral doses of 10&nbsp;mg and 80&nbsp;mg of vardenafil have been shown to prolong the QTc interval by a mean of 8&nbsp;msec and 10&nbsp;msec, respectively. And single doses of 10&nbsp;mg vardenafil co-administered concomitantly with 400&nbsp;mg gatifloxacin, an active substance with comparable QT effect, showed an additive QTc effect of 4&nbsp;msec when compared to either active substance alone. The clinical impact of these QT changes is unknown (see section 5.1).</p><p>The clinical relevance of this finding is unknown and cannot be generalised to all patients under all circumstances, as it will depend on the individual risk factors and susceptibilities that may be present at any time in any given patient. Medicinal products that may prolong QTc interval, including vardenafil, are best avoided in patients with relevant risk factors, for example, hypokalaemia, congenital QT prolongation, concomitant administration of antiarrhythmic medicinal products in Class 1A (e.g. quinidine, procainamide), or Class III (e.g. amiodarone, sotalol).</p><p>&nbsp;</p><p><em>Effect on vision</em></p><p>Visual defects and cases of non-arteritic ischemic optic neuropathy (NAION) have been reported in connection with the intake of Levitra and other PDE5 inhibitors. Analyses of observational data suggest an increased risk of acute NAION in men with erectile dysfunction following exposure to PDE5 inhibitors such as vardenafil, tadalafil and sildenafil (see section 4.8). As this may be relevant for all patients exposed to vardenafil the patient should be advised that in the case of sudden visual defect, he should stop taking Levitra and consult immediately a physician (see section 4.3).</p><p>&nbsp;</p><p><em>Effect on bleeding</em></p><p><em>In vitro</em> studies with human platelets indicate that vardenafil has no antiaggregatory effect on its own, but at high (super-therapeutic) concentrations vardenafil potentiates the antiaggregatory effect of the nitric oxide donor sodium nitroprusside. In humans vardenafil had no effect on bleeding time alone or in combination with acetylsalicyclic acid (see section 4.5). There is no safety information available on the administration of vardenafil to patients with bleeding disorders or active peptic ulceration. Therefore vardenafil should be administered to these patients only after careful benefit-risk assessment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Effects of other medicinal products on vardenafil</u></p><p><em>In vitro </em>studies</p><p>Vardenafil is metabolised predominantly by hepatic enzymes via cytochrome P450 (CYP) isoform 3A4, with some contribution from CYP3A5 and CYP2C isoforms. Therefore, inhibitors of these isoenzymes may reduce vardenafil clearance.</p><p><em>&nbsp;</em></p><p><em>In vivo </em>studies</p><p>Co-administration of the HIV protease inhibitor indinavir (800&nbsp;mg&nbsp;three times a day), a potent CYP3A4 inhibitor, with vardenafil (10&nbsp;mg film-coated tablets) resulted in a 16‑fold increase in vardenafil AUC and a 7‑fold increase in vardenafil C<sub>max</sub>. At 24 hours, the plasma levels of vardenafil had fallen to approximately 4% of the maximum vardenafil plasma level (C<sub>max</sub>).</p><p>&nbsp;</p><p>Co-administration of vardenafil with ritonavir (600&nbsp;mg twice daily) resulted in a 13-fold increase in vardenafil C<sub>max</sub> and a 49-fold increase in vardenafil AUC<sub>0-24</sub> when co-administered with vardenafil 5&nbsp;mg. The interaction is a consequence of blocking hepatic metabolism of vardenafil by ritonavir, a highly potent CYP3A4 inhibitor, which also inhibits CYP2C9. Ritonavir significantly prolonged the half-life of vardenafil to 25.7 hours (see section 4.3).</p><p>&nbsp;</p><p>Co-administration of ketoconazole (200&nbsp;mg), a potent CYP3A4 inhibitor, with vardenafil (5&nbsp;mg) resulted in a 10‑fold increase in vardenafil AUC and a 4‑fold increase in vardenafil C<sub>max</sub> (see section 4.4).</p><p>&nbsp;</p><p>Although specific interaction studies have not been conducted, the concomitant use of other potent CYP3A4 inhibitors (such as itraconazole) can be expected to produce vardenafil plasma levels comparable to those produced by ketoconazole. Concomitant use of vardenafil with potent CYP3A4 inhibitors such as itraconazole and ketoconazole (oral use) should be avoided (see sections 4.3 and 4.4). In men older than 75 years the concomitant use of vardenafil with itraconazole or ketoconazole is contraindicated (see section 4.3).</p><p>&nbsp;</p><p>Co-administration of erythromycin (500&nbsp;mg&nbsp;three times a day), a CYP3A4 inhibitor, with vardenafil (5&nbsp;mg) resulted in a 4‑fold increase in vardenafil AUC and a 3‑fold increase in C<sub>max</sub>. Although a specific interaction study has not been conducted, the co-administration of clarithromycin can be expected to result in similar effects on vardenafil AUC and C<sub>max</sub>. When used in combination with a moderate CYP3A4 inhibitor such as<em> </em>erythromycin or clarithromycin, vardenafil dose adjustment might be necessary (see sections 4.2 and 4.4). Cimetidine (400&nbsp;mg&nbsp;twice daily), a non-specific cytochrome P450 inhibitor, had no effect on vardenafil AUC and C<sub>max</sub> when co-administered with vardenafil (20&nbsp;mg) to healthy volunteers.</p><p>&nbsp;</p><p>Grapefruit juice being a weak inhibitor of CYP3A4 gut wall metabolism, may give rise to modest increases in plasma levels of vardenafil (see section 4.4).</p><p>&nbsp;</p><p>The pharmacokinetics of vardenafil (20&nbsp;mg) was not affected by co-administration with the H2‑antagonist ranitidine (150&nbsp;mg twice daily), digoxin, warfarin, glibenclamide, alcohol (mean maximum blood alcohol level of 73&nbsp;mg/dl) or single doses of antacid (magnesium hydroxide/aluminium hydroxide).</p><p>&nbsp;</p><p>Although specific interaction studies were not conducted for all medicinal products, population pharmacokinetic analysis showed no effect on vardenafil pharmacokinetics of the following concomitant medicinal products: acetylsalicylic acid, ACE-inhibitors, beta-blockers, weak CYP3A4 inhibitors, diuretics and medicinal products for the treatment of diabetes (sulfonylureas and metformin).</p><p>&nbsp;</p><p><u>Effects of vardenafil on other medicinal products</u></p><p>There are no data on the interaction of vardenafil and non-specific phosphodiesterase inhibitors such as theophylline or dipyridamole.</p><p>&nbsp;</p><p><em>In vivo </em>studies</p><p>No potentiation of the blood pressure lowering effect of sublingual nitroglycerin (0.4&nbsp;mg) was observed when vardenafil (10&nbsp;mg) was given at varying time intervals (1&nbsp;h to 24&nbsp;h) prior to the dose of nitroglycerin in a study in 18 healthy male subjects. Vardenafil 20 mg film-coated tablets potentiated the blood pressure lowering effect of sublingual nitroglycerin (0.4&nbsp;mg) taken 1 and 4 hours after vardenafil administration to healthy middle aged subjects. No effect on blood pressure was observed when nitroglycerin was taken 24 hours after administration of a single dose of vardenafil 20 mg film-coated tablets. However, there is no information on the possible potentiation of the hypotensive effects of nitrates by vardenafil in patients, and concomitant use is therefore contraindicated (see section 4.3).</p><p>&nbsp;</p><p>Nicorandil is a hybrid of potassium channel opener and nitrate. Due to the nitrate component it has the potential to have serious interaction with vardenafil.</p><p>&nbsp;</p><p>Since alpha-blocker monotherapy can cause marked lowering of blood pressure, especially postural hypotension and syncope, interaction studies were conducted with vardenafil. In two interaction studies with healthy normotensive volunteers after forced titration of the alpha-blockers tamsulosin or terazosin to high doses, hypotension (in some cases symptomatic) was reported in a significant number of subjects after co-administration of vardenafil. Among subjects treated with terazosin, hypotension was observed more frequently when vardenafil and terazosin were given simultaneously than when the dosing was separated by a time interval of 6 hours.</p><p>&nbsp;</p><p>Based on the results of interaction studies conducted with vardenafil in patients with benign prostatic hyperplasia (BPH) on stable tamsulosin, terazosin or alfuzosin therapy:</p><p>&nbsp;</p><p style="margin-left:28.35pt; text-indent:-28.35pt"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->When vardenafil (film-coated tablets) was given at doses of 5, 10 or 20&nbsp;mg on a background of stable therapy with tamsulosin, there was no symptomatic reduction in blood pressure, although 3/21 tamsulosin treated subjects exhibited transient standing systolic blood pressures of less than 85&nbsp;mmHg.</p><p style="margin-left:28.35pt; text-indent:-28.35pt"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->When vardenafil 5&nbsp;mg (film-coated tablets) was given simultaneously with terazosin 5 or 10&nbsp;mg, one of 21 patients experienced symptomatic postural hypotension. Hypotension was not observed when vardenafil 5&nbsp;mg and terazosin administration was separated by 6 hours.</p><p style="margin-left:28.35pt; text-indent:-28.35pt"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->When vardenafil (film-coated tablets) was given at doses of 5 or 10 mg on a background of stable therapy with alfuzosin, compared to placebo, there was no symptomatic reduction in blood pressure.&nbsp;</p><p>&nbsp;</p><p>Therefore, concomitant treatment should be initiated only if the patient is stable on his alpha-blocker therapy. In those patients who are stable on alpha-blocker therapy, vardenafil should be initiated at the lowest recommended starting dose of 5&nbsp;mg. Levitra may be administered at any time with tamsulosin or alfuzosin. With other alpha-blockers a time separation of dosing should be considered when vardenafil is prescribed concomitantly (see<strong> </strong>section 4.4).</p><p>&nbsp;</p><p>No significant interactions were shown when warfarin (25&nbsp;mg), which is metabolised by CYP2C9, or digoxin (0.375&nbsp;mg) was co-administered with vardenafil (20&nbsp;mg film-coated tablets). The relative bioavailability of glibenclamide (3.5&nbsp;mg) was not affected when co-administered with vardenafil (20&nbsp;mg). In a specific study, where vardenafil (20&nbsp;mg) was co-administered with slow release nifedipine (30&nbsp;mg or 60&nbsp;mg) in hypertensive patients, there was an additional reduction on supine systolic blood pressure of 6&nbsp;mmHg and supine diastolic blood pressure of 5&nbsp;mmHg accompanied with an increase in heart rate of 4&nbsp;bpm.</p><p>&nbsp;</p><p>When vardenafil (20&nbsp;mg film-coated tablets) and alcohol (mean maximum blood alcohol level of 73&nbsp;mg/dl) were taken together, vardenafil did not potentiate the effects of alcohol on blood pressure and heart rate and the pharmacokinetics of vardenafil were not altered.</p><p>&nbsp;</p><p>Vardenafil (10&nbsp;mg) did not potentiate the increase in bleeding time caused by acetylsalicylic acid (2&nbsp;x&nbsp;81&nbsp;mg).</p><p>&nbsp;</p><p><u>Riociguat</u></p><p>Preclinical studies showed additive systemic blood pressure lowering effect when PDE5 inhibitors were combined with riociguat. In clinical studies, riociguat has been shown to augment the hypotensive effects of PDE5 inhibitors. There was no evidence of favourable clinical effect of the combination in the population studied. Concomitant use of riociguat with PDE5 inhibitors, including vardenafil, is contraindicated (see section 4.3).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Levitra is not indicated for use by women. There are no studies of vardenafil in pregnant women.</p><p>There are no fertility data available.</p><p>&nbsp;</p><p>In animal reproduction studies conducted in pregnant rats and rabbits, no adverse developmental outcomes were observed with oral administration of vardenafil.</p><p>&nbsp;</p><p>There is no information on the presence of vardenafil and its major metabolite in human milk, the effects on the breastfed infant, or the effects on milk production. Vardenafil is present in the milk of lactating rats.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>No studies on the effects on the ability to drive and use machines have been performed.</p><p>&nbsp;</p><p>As dizziness and abnormal vision have been reported in clinical trials with vardenafil, patients should be aware of how they react to Levitra, before driving or operating machines.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Summary of the safety profile</u></p><p>The adverse reactions reported with Levitra film-coated tablets or 10&nbsp;mg orodispersible tablets in clinical trials were generally transient and mild to moderate in nature. The most commonly reported adverse drug reaction occurring in &sup3;&nbsp;10% of patients is headache.</p><p>&nbsp;</p><p><u>Tabulated list of adverse reactions</u></p><p>Adverse reactions are listed according to the MedDRA frequency convention: very common (&ge;1/10), common (&ge;1/100 to &lt;1/10), uncommon (&sup3;1/1,000 to &lt;1/100), rare (&sup3;1/10,000 to &lt;1/1,000) and not known (can not be estimated from available data).</p><p>&nbsp;</p><p>Within each frequency grouping, adverse reactions are presented in order of decreasing seriousness.</p><p>&nbsp;</p><p>The following adverse reactions have been reported:</p><p><strong>&nbsp;</strong></p><table cellspacing="0" cellpadding="0" border="1" style="width:609px"><thead><tr><td style="height:.1in; vertical-align:top; width:74.4pt"><p style="margin-left:0in; margin-right:-.1pt"><strong>System Organ Class</strong></p></td><td style="height:.1in; vertical-align:top; width:75.25pt"><p style="margin-left:0in; margin-right:-.1pt"><strong>Very common</strong></p><p style="margin-left:0in; margin-right:-.1pt">(&sup3;1/10)</p></td><td style="height:.1in; vertical-align:top; width:63.5pt"><p style="margin-left:0in; margin-right:-.1pt"><strong>Common</strong></p><p style="margin-left:0in; margin-right:0in">(&sup3;1/100 to &lt;1/10)</p></td><td style="height:.1in; vertical-align:top; width:78.0pt"><p style="margin-left:0in; margin-right:-.1pt"><strong>Uncommon</strong></p><p style="margin-left:0in; margin-right:-.1pt">(&sup3;1/1,000 to &lt;1/100)</p></td><td style="height:.1in; vertical-align:top; width:89.7pt"><p style="margin-left:0in; margin-right:-.1pt"><strong>Rare</strong></p><p style="margin-left:0in; margin-right:0in">(&sup3;1/10,000 to &lt;1/1,000)</p></td><td style="height:.1in; vertical-align:top; width:76.25pt"><p style="margin-left:0in; margin-right:0in"><strong>Not known </strong></p><p style="margin-left:0in; margin-right:0in">(cannot be estimated from the available data)</p></td></tr></thead><tbody><tr><td style="height:.1in; vertical-align:top; width:74.4pt"><p style="margin-left:0in; margin-right:-.1pt"><strong>Infection and infestations</strong></p></td><td style="height:.1in; vertical-align:top; width:75.25pt"><p style="margin-left:0in; margin-right:-.1pt">&nbsp;</p></td><td style="height:.1in; vertical-align:top; width:63.5pt"><p style="margin-left:0in; margin-right:-.1pt">&nbsp;</p></td><td style="height:.1in; vertical-align:top; width:78.0pt"><p style="margin-left:0in; margin-right:-.1pt">&nbsp;</p></td><td style="height:.1in; vertical-align:top; width:89.7pt"><p style="margin-left:0in; margin-right:-.1pt">Conjunctivitis</p></td><td style="height:.1in; vertical-align:top; width:76.25pt"><p style="margin-left:0in; margin-right:-.1pt">&nbsp;</p></td></tr><tr><td style="height:.1in; vertical-align:top; width:74.4pt"><p style="margin-left:0in; margin-right:-.1pt"><strong>Immune system disorders</strong></p></td><td style="height:.1in; vertical-align:top; width:75.25pt"><p style="margin-left:0in; margin-right:-.1pt">&nbsp;</p></td><td style="height:.1in; vertical-align:top; width:63.5pt"><p style="margin-left:0in; margin-right:-.1pt">&nbsp;</p></td><td style="height:.1in; vertical-align:top; width:78.0pt"><p style="margin-left:0in; margin-right:0in">Allergic oedema and angioedema</p></td><td style="height:.1in; vertical-align:top; width:89.7pt"><p style="margin-left:0in; margin-right:-.1pt">Allergic reaction</p></td><td style="height:.1in; vertical-align:top; width:76.25pt"><p style="margin-left:0in; margin-right:-.1pt">&nbsp;</p></td></tr><tr><td style="height:33.05pt; vertical-align:top; width:74.4pt"><p style="margin-left:0in; margin-right:-.1pt"><strong>Psychiatric disorders</strong></p></td><td style="height:33.05pt; vertical-align:top; width:75.25pt"><p style="margin-left:0in; margin-right:-.1pt">&nbsp;</p></td><td style="height:33.05pt; vertical-align:top; width:63.5pt"><p style="margin-left:0in; margin-right:-.1pt">&nbsp;</p></td><td style="height:33.05pt; vertical-align:top; width:78.0pt"><p style="margin-left:0in; margin-right:-.1pt">Sleep disorder</p></td><td style="height:33.05pt; vertical-align:top; width:89.7pt"><p style="margin-left:0in; margin-right:-.1pt">Anxiety</p></td><td style="height:33.05pt; vertical-align:top; width:76.25pt"><p style="margin-left:0in; margin-right:-.1pt">&nbsp;</p></td></tr><tr><td style="height:.1in; vertical-align:top; width:74.4pt"><p style="margin-left:0in; margin-right:-.1pt"><strong>Nervous system disorders</strong></p></td><td style="height:.1in; vertical-align:top; width:75.25pt"><p style="margin-left:0in; margin-right:-.1pt">Headache</p></td><td style="height:.1in; vertical-align:top; width:63.5pt"><p style="margin-left:0in; margin-right:-.1pt">Dizziness</p></td><td style="height:.1in; vertical-align:top; width:78.0pt"><p style="margin-left:0in; margin-right:-.1pt">Somnolence</p><p style="margin-left:0in; margin-right:-.1pt">Paraesthesia and dysaesthesia</p></td><td style="height:.1in; vertical-align:top; width:89.7pt"><p style="margin-left:0in; margin-right:-.1pt">Syncope</p><p style="margin-left:0in; margin-right:-.1pt">Seizure</p><p style="margin-left:0in; margin-right:-.1pt">Amnesia</p><p style="margin-left:0in; margin-right:-.1pt">Transient ischaemic attack</p></td><td style="height:.1in; vertical-align:top; width:76.25pt"><p style="margin-left:0in; margin-right:-.1pt">Cerebral haemorrhage</p></td></tr><tr><td style="height:.1in; vertical-align:top; width:74.4pt"><p style="margin-left:0in; margin-right:-.1pt"><strong>Eye disorders </strong></p></td><td style="height:.1in; vertical-align:top; width:75.25pt"><p style="margin-left:0in; margin-right:-.1pt">&nbsp;</p></td><td style="height:.1in; vertical-align:top; width:63.5pt"><p style="margin-left:0in; margin-right:-.1pt">&nbsp;</p></td><td style="height:.1in; vertical-align:top; width:78.0pt"><p style="margin-left:0in; margin-right:-.1pt">Visual disturbance</p><p style="margin-left:0in; margin-right:-.1pt">Ocular hyperaemia</p><p style="margin-left:0in; margin-right:-.1pt">Visual colour distortions</p><p style="margin-left:0in; margin-right:-.1pt">Eye pain and eye discomfort</p><p style="margin-left:0in; margin-right:-.1pt">Photophobia</p></td><td style="height:.1in; vertical-align:top; width:89.7pt"><p style="margin-left:0in; margin-right:-.1pt">Increase in intraocular pressure</p><p style="margin-left:0in; margin-right:-.1pt">Lacrimation increased</p></td><td style="height:.1in; vertical-align:top; width:76.25pt"><p style="margin-left:0in; margin-right:-.1pt">Non-arteritic anterior ischemic optic neuropathy</p><p style="margin-left:0in; margin-right:-.1pt">Visual defects</p></td></tr><tr><td style="height:.1in; vertical-align:top; width:74.4pt"><p style="margin-left:0in; margin-right:-.1pt"><strong>Ear and labyrinth disorders</strong></p></td><td style="height:.1in; vertical-align:top; width:75.25pt"><p style="margin-left:0in; margin-right:-.1pt">&nbsp;</p></td><td style="height:.1in; vertical-align:top; width:63.5pt"><p style="margin-left:0in; margin-right:-.1pt">&nbsp;</p></td><td style="height:.1in; vertical-align:top; width:78.0pt"><p style="margin-left:0in; margin-right:-.1pt">Tinnitus</p><p style="margin-left:0in; margin-right:-.1pt">Vertigo</p></td><td style="height:.1in; vertical-align:top; width:89.7pt"><p style="margin-left:0in; margin-right:-.1pt">&nbsp;</p></td><td style="height:.1in; vertical-align:top; width:76.25pt"><p style="margin-left:0in; margin-right:-.1pt">Sudden deafness</p></td></tr><tr><td style="height:.1in; vertical-align:top; width:74.4pt"><p style="margin-left:0in; margin-right:-.1pt"><strong>Cardiac disorders </strong></p></td><td style="height:.1in; vertical-align:top; width:75.25pt"><p style="margin-left:0in; margin-right:-.1pt">&nbsp;</p></td><td style="height:.1in; vertical-align:top; width:63.5pt"><p style="margin-left:0in; margin-right:-.1pt">&nbsp;</p></td><td style="height:.1in; vertical-align:top; width:78.0pt"><p style="margin-left:0in; margin-right:-.1pt">Palpitation</p><p style="margin-left:0in; margin-right:-.1pt">Tachycardia</p></td><td style="height:.1in; vertical-align:top; width:89.7pt"><p style="margin-left:0in; margin-right:-.1pt">Myocardial infarction</p><p style="margin-left:0in; margin-right:-.1pt">Ventricular tachy-arrhythmias</p><p style="margin-left:0in; margin-right:-.1pt">Angina pectoris</p></td><td style="height:.1in; vertical-align:top; width:76.25pt"><p style="margin-left:0in; margin-right:-.1pt">Sudden death</p></td></tr><tr><td style="height:.1in; vertical-align:top; width:74.4pt"><p style="margin-left:0in; margin-right:-.1pt"><strong>Vascular disorders </strong></p></td><td style="height:.1in; vertical-align:top; width:75.25pt"><p style="margin-left:0in; margin-right:-.1pt">&nbsp;</p></td><td style="height:.1in; vertical-align:top; width:63.5pt"><p style="margin-left:0in; margin-right:-.1pt">Flushing</p></td><td style="height:.1in; vertical-align:top; width:78.0pt"><p style="margin-left:0in; margin-right:-.1pt">&nbsp;</p></td><td style="height:.1in; vertical-align:top; width:89.7pt"><p style="margin-left:0in; margin-right:-.1pt">Hypotension</p><p style="margin-left:0in; margin-right:-.1pt">Hypertension</p></td><td style="height:.1in; vertical-align:top; width:76.25pt"><p style="margin-left:0in; margin-right:-.1pt">&nbsp;</p></td></tr><tr><td style="height:.1in; vertical-align:top; width:74.4pt"><p style="margin-left:0in; margin-right:-.1pt"><strong>Respiratory, thoracic and mediastinal disorders</strong></p></td><td style="height:.1in; vertical-align:top; width:75.25pt"><p style="margin-left:0in; margin-right:-.1pt">&nbsp;</p></td><td style="height:.1in; vertical-align:top; width:63.5pt"><p style="margin-left:0in; margin-right:0in">Nasal congestion</p></td><td style="height:.1in; vertical-align:top; width:78.0pt"><p style="margin-left:0in; margin-right:-.1pt">Dyspnoea</p><p style="margin-left:0in; margin-right:0in">Sinus congestion</p></td><td style="height:.1in; vertical-align:top; width:89.7pt"><p style="margin-left:0in; margin-right:-.1pt">Epistaxis</p></td><td style="height:.1in; vertical-align:top; width:76.25pt"><p style="margin-left:0in; margin-right:-.1pt">&nbsp;</p></td></tr><tr><td style="height:.1in; vertical-align:top; width:74.4pt"><p style="margin-left:0in; margin-right:-.1pt"><strong>Gastrointesti&shy;nal disorders </strong></p></td><td style="height:.1in; vertical-align:top; width:75.25pt"><p style="margin-left:0in; margin-right:-.1pt">&nbsp;</p></td><td style="height:.1in; vertical-align:top; width:63.5pt"><p style="margin-left:0in; margin-right:-.1pt">Dyspepsia</p></td><td style="height:.1in; vertical-align:top; width:78.0pt"><p style="margin-left:0in; margin-right:-.1pt">Gastro-oesophageal reflux disease</p><p style="margin-left:0in; margin-right:-.1pt">Gastritis</p><p style="margin-left:0in; margin-right:-.1pt">Gastrointestinal and abdominal pain</p><p style="margin-left:0in; margin-right:-.1pt">Diarrhoea</p><p style="margin-left:0in; margin-right:-.1pt">Vomiting</p><p style="margin-left:0in; margin-right:-.1pt; text-align:justify">Nausea</p><p style="margin-left:0in; margin-right:-.1pt">Dry mouth</p></td><td style="height:.1in; vertical-align:top; width:89.7pt"><p style="margin-left:0in; margin-right:-.1pt">&nbsp;</p></td><td style="height:.1in; vertical-align:top; width:76.25pt"><p style="margin-left:0in; margin-right:-.1pt">&nbsp;</p></td></tr><tr><td style="height:.1in; vertical-align:top; width:74.4pt"><p style="margin-left:0in; margin-right:-.1pt"><strong>Hepatobiliary disorders</strong></p></td><td style="height:.1in; vertical-align:top; width:75.25pt"><p style="margin-left:0in; margin-right:-.1pt">&nbsp;</p></td><td style="height:.1in; vertical-align:top; width:63.5pt"><p style="margin-left:0in; margin-right:-.1pt">&nbsp;</p></td><td style="height:.1in; vertical-align:top; width:78.0pt"><p style="margin-left:0in; margin-right:-.1pt">Increase in transaminases</p></td><td style="height:.1in; vertical-align:top; width:89.7pt"><p style="margin-left:0in; margin-right:-.1pt">Increase in gamma-glutamyl transferase</p></td><td style="height:.1in; vertical-align:top; width:76.25pt"><p style="margin-left:0in; margin-right:-.1pt">&nbsp;</p></td></tr><tr><td style="height:40.55pt; vertical-align:top; width:74.4pt"><p style="margin-left:0in; margin-right:-.1pt"><strong>Skin and subcutaneous tissue disorders</strong></p></td><td style="height:40.55pt; vertical-align:top; width:75.25pt"><p style="margin-left:0in; margin-right:-.1pt">&nbsp;</p></td><td style="height:40.55pt; vertical-align:top; width:63.5pt"><p style="margin-left:0in; margin-right:-.1pt">&nbsp;</p></td><td style="height:40.55pt; vertical-align:top; width:78.0pt"><p style="margin-left:0in; margin-right:-.1pt">Erythema</p><p style="margin-left:0in; margin-right:-.1pt">Rash</p></td><td style="height:40.55pt; vertical-align:top; width:89.7pt"><p style="margin-left:0in; margin-right:-.1pt">Photosensitivity reaction</p></td><td style="height:40.55pt; vertical-align:top; width:76.25pt"><p style="margin-left:0in; margin-right:-.1pt">&nbsp;</p></td></tr><tr><td style="height:121.25pt; vertical-align:top; width:74.4pt"><p style="margin-left:0in; margin-right:-.1pt"><strong>Musculoskele&shy;tal and connective tissue disorders</strong></p></td><td style="height:121.25pt; vertical-align:top; width:75.25pt"><p style="margin-left:0in; margin-right:-.1pt">&nbsp;</p></td><td style="height:121.25pt; vertical-align:top; width:63.5pt"><p style="margin-left:0in; margin-right:-.1pt">&nbsp;</p></td><td style="height:121.25pt; vertical-align:top; width:78.0pt"><p style="margin-left:0in; margin-right:-.1pt">Back pain</p><p style="margin-left:0in; margin-right:-.1pt">Increase in creatine phosphokinase</p><p style="margin-left:0in; margin-right:0in">Myalgia</p><p style="margin-left:0in; margin-right:-.1pt">Increased muscle tone and cramping</p></td><td style="height:121.25pt; vertical-align:top; width:89.7pt"><p style="margin-left:0in; margin-right:-.1pt">&nbsp;</p></td><td style="height:121.25pt; vertical-align:top; width:76.25pt"><p style="margin-left:0in; margin-right:-.1pt">&nbsp;</p></td></tr><tr><td style="height:51.05pt; vertical-align:top; width:74.4pt"><p style="margin-right:0in"><strong>Renal and urinary disorders</strong></p></td><td style="height:51.05pt; vertical-align:top; width:75.25pt"><p>&nbsp;</p></td><td style="height:51.05pt; vertical-align:top; width:63.5pt"><p>&nbsp;</p></td><td style="height:51.05pt; vertical-align:top; width:78.0pt"><p>&nbsp;</p></td><td style="height:51.05pt; vertical-align:top; width:89.7pt"><p>&nbsp;</p></td><td style="height:51.05pt; vertical-align:top; width:76.25pt"><p>Haematuria</p></td></tr><tr><td style="height:51.05pt; vertical-align:top; width:74.4pt"><p style="margin-right:0in"><strong>Reproductive system and breast disorders</strong></p></td><td style="height:51.05pt; vertical-align:top; width:75.25pt"><p>&nbsp;</p></td><td style="height:51.05pt; vertical-align:top; width:63.5pt"><p>&nbsp;</p></td><td style="height:51.05pt; vertical-align:top; width:78.0pt"><p>Increase in erection</p></td><td style="height:51.05pt; vertical-align:top; width:89.7pt"><p>Priapism</p></td><td style="height:51.05pt; vertical-align:top; width:76.25pt"><p>Penile Haemorrhage Haematosper&shy;mia</p></td></tr><tr><td style="height:64.25pt; vertical-align:top; width:74.4pt"><p style="margin-left:0in; margin-right:-.1pt"><strong>General disorders and administra&shy;tion site conditions</strong></p></td><td style="height:64.25pt; vertical-align:top; width:75.25pt"><p style="margin-left:0in; margin-right:-.1pt"><strong>&nbsp;</strong></p></td><td style="height:64.25pt; vertical-align:top; width:63.5pt"><p style="margin-left:0in; margin-right:-.1pt"><strong>&nbsp;</strong></p></td><td style="height:64.25pt; vertical-align:top; width:78.0pt"><p style="margin-left:0in; margin-right:-.1pt">Feeling unwell</p></td><td style="height:64.25pt; vertical-align:top; width:89.7pt"><p style="margin-left:0in; margin-right:-.1pt">Chest pain</p></td><td style="height:64.25pt; vertical-align:top; width:76.25pt"><p style="margin-left:0in; margin-right:-.1pt">&nbsp;</p></td></tr></tbody></table><p>&nbsp;</p><p><u>Description of selected adverse reactions</u></p><p>Penile haemorrhage, haematospermia and haematuria have been reported in clinical trials and spontaneous post-marketing data with the use of all PDE5 inhibitors, including vardenafil.</p><p>&nbsp;</p><p>At a dose of 20&nbsp;mg Levitra film-coated tablets, elderly (&ge;65 years old) patients had higher frequencies of headaches (16.2% versus 11.8%) and dizziness (3.7% versus 0.7%) than younger patients (&lt;65 years old). In general, the incidence of adverse reactions (especially &ldquo;dizziness&rdquo;) has been shown to be slightly higher in patients with a history of hypertension.</p><p>&nbsp;</p><p><u>Reporting of suspected adverse reactions</u></p><p>Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product.</p><p>&nbsp;</p><p><strong>To report any side effect(s):</strong></p><p>The National Pharmacovigilance Centre (NPC).</p><p>Fax: + 966 - 11 - 205 - 7662.</p><p>SFDA call center: 19999.</p><p>Email: npc.drug@sfda.gov.sa</p><p>Website: https://ade.sfda.gov.sa</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>In single dose volunteer studies, doses up to and including 80&nbsp;mg vardenafil (film-coated tablets) per day were tolerated without exhibiting serious adverse reactions.</p><p>&nbsp;</p><p>When vardenafil was administered in higher doses and more frequently than the recommended dose regimen (40&nbsp;mg&nbsp;film-coated tablets twice daily) cases of severe back pain have been reported. This was not associated with any muscle or neurological toxicity.</p><p>&nbsp;</p><p>In cases of overdose, standard supportive measures should be adopted as required. Renal dialysis is not expected to accelerate clearance, as vardenafil is highly bound to plasma proteins and not significantly eliminated in the urine.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmacotherapeutic group: Urologicals, Drugs used in erectile dysfunction, ATC code: G04BE09.</p><p>&nbsp;</p><p>Vardenafil is an oral therapy for the improvement of erectile function in men with erectile dysfunction. In the natural setting, i.e. with sexual stimulation, it restores impaired erectile function by increasing blood flow to the penis.</p><p>&nbsp;</p><p>Penile erection is a haemodynamic process. During sexual stimulation, nitric oxide is released. It activates the enzyme guanylate cyclase, resulting in an increased level of cyclic guanosine monophosphate (cGMP) in the corpus cavernosum. This in turn results in smooth muscle relaxation, allowing increased inflow of blood into the penis. The level of cGMP is regulated by the rate of synthesis via guanylate cyclase and by the rate of degradation via cGMP hydrolysing phosphodiesterases (PDEs).</p><p>&nbsp;</p><p>Vardenafil is a potent and selective inhibitor of the cGMP specific phosphodiesterase type 5 (PDE5), the most prominent PDE in the human corpus cavernosum. Vardenafil potently enhances the effect of endogenous nitric oxide in the corpus cavernosum by inhibiting PDE5. When nitric oxide is released in response to sexual stimulation, inhibition of PDE5 by vardenafil results in increased corpus cavernosum levels of cGMP. Sexual stimulation is therefore required for vardenafil to produce its beneficial therapeutic effects.</p><p>&nbsp;</p><p><em>In vitro</em> studies have shown that vardenafil is more potent on PDE5 than on other known phosphodiesterases (&gt;15‑fold relative to PDE6, &gt;130‑fold relative to PDE1, &gt;300‑fold relative to PDE11, and &gt;1000‑fold relative to PDE2, PDE3, PDE4, PDE7, PDE8, PDE9 and PDE10).</p><p>&nbsp;</p><p>In a penile plesthysmography (RigiScan) study, vardenafil 20&nbsp;mg produced erections considered sufficient for penetration (60% rigidity by RigiScan) in some men as early as 15 minutes after dosing. The overall response of these subjects to vardenafil became statistically significant, compared to placebo, 25 minutes after dosing.</p><p>&nbsp;</p><p>Vardenafil causes mild and transient decreases in blood pressure which, in the majority of the cases, do not translate into clinical effects. The mean maximum decreases in supine systolic blood pressure following 20&nbsp;mg and 40&nbsp;mg vardenafil were &ndash;&nbsp;6.9&nbsp;mmHg under 20&nbsp;mg and &ndash;&nbsp;4.3&nbsp;mmHg under 40&nbsp;mg of vardenafil, when compared to placebo. These effects are consistent with the vasodilatory effects of PDE5-inhibitors and are probably due to increased cGMP levels in vascular smooth muscle cells. Single and multiple oral doses of vardenafil up to 40&nbsp;mg produced no clinically relevant changes in the ECGs of normal male volunteers.</p><p>&nbsp;</p><p>A single dose, double blind, crossover, randomised trial in 59 healthy males compared the effects on the QT interval of vardenafil (10&nbsp;mg and 80&nbsp;mg), sildenafil (50&nbsp;mg and 400&nbsp;mg) and placebo. Moxifloxacin (400&nbsp;mg) was included as an active internal control. Effects on the QT interval were measured one hour post-dose (average t<sub>max </sub>for vardenafil). The primary objective of this study was to rule out a greater than 10&nbsp;msec effect (i.e. to demonstrate lack of effect) of a single 80&nbsp;mg oral dose of vardenafil on QTc interval compared to placebo, as measured by the change in Fridericia&#39;s correction formula (QTcF=QT/RR1/3) from baseline at the 1 hour post-dose time point. The vardenafil results showed an increase in QTc (Fridericia) of 8&nbsp;msec (90% CI: 6-9) and 10&nbsp;msec (90% CI: 8-11) at 10 and 80&nbsp;mg doses compared to placebo and an increase in QTci of 4&nbsp;msec (90% CI: 3-6) and 6&nbsp;msec (90% CI: 4-7) at 10 and 80&nbsp;mg doses compared to placebo, at one hour post-dose. At t<sub>max</sub>, only the mean change in QTcF for vardenafil 80&nbsp;mg was out of the study established limit (mean 10&nbsp;msec, 90% CI: 8-11). When using the individual correction formulae, none of the values were out of the limit.</p><p>&nbsp;</p><p>In a separate post‑marketing study of 44 healthy volunteers, single doses of 10&nbsp;mg vardenafil or 50&nbsp;mg sildenafil were co-administered concomitantly with 400&nbsp;mg gatifloxacin, a drug with comparable QT effect. Both vardenafil and sildenafil showed an increase of Fridericia QTc effect of 4&nbsp;msec (vardenafil) and 5&nbsp;msec (sildenafil) when compared to either drug alone. The actual clinical impact of these QT changes is unknown.</p><p>&nbsp;</p><p><u>Further information on clinical trials with vardenafil 10&nbsp;mg orodispersible tablets</u></p><p>Efficacy and safety of vardenafil 10&nbsp;mg orodispersible tablets were separately demonstrated in a broad population in two studies including 701&nbsp;randomized erectile dysfunction patients who were treated up to 12&nbsp;weeks. The distribution of patients in the predefined subgroups was covering elderly patients (51%), patients with history of diabetes mellitus (29%), dyslipidemia (39%) and hypertension (40%).</p><p>&nbsp;</p><p>In pooled data from the two vardenafil 10&nbsp;mg orodispersible tablets trials, IIEF-EF domain scores were significantly higher with vardenafil 10&nbsp;mg orodispersible tablet versus placebo.</p><p>&nbsp;</p><p>A percentage of 71% of all sexual attempts reported in the clinical trials had successful penetration compared to 44% of all attempts in the placebo group. These results were also reflected in subgroups, in elderly patients (65%), in patients with history of diabetes mellitus (63%), patients with history of dyslipidemia (66%) and hypertension (70%) of all sexual attempts reported had successful penetration.</p><p>&nbsp;</p><p>About 63% of all reported sexual attempts with vardenafil 10&nbsp;mg orodispersible tablets were successful in terms of erection maintenance compared to about 26% of all placebo-controlled sexual attempts. In the predefined subgroups 57% (elderly patients), 56% (patients with history of diabetes mellitus), 59% (patients with history of dyslipidemia) and 60% (patients with history of hypertension) of all reported attempts with vardenafil 10&nbsp;mg orodispersible tablets were successful in terms of maintenance of erection.</p><p>&nbsp;</p><p><u>Further information on clinical trials</u></p><p>In clinical trials vardenafil was administered to over 17,000 men with erectile dysfunction (ED) aged 18&nbsp;‑&nbsp;89 years, many of whom had multiple co-morbid conditions. Over 2,500 patients have been treated with vardenafil for six months or longer. Of these, 900 patients have been treated for one year or longer.</p><p>&nbsp;</p><p>The following patient groups were represented: elderly (22%), patients with hypertension (35%), diabetes mellitus (29%), ischaemic heart disease and other cardiovascular diseases (7%), chronic pulmonary disease (5%), hyperlipidaemia (22%), depression (5%), radical prostatectomy (9%). The following groups were not well represented in clinical trials: elderly (&gt;75 years, 2.4%), and patients with certain cardiovascular conditions (see section 4.3). No clinical trials in CNS diseases (except spinal cord injury), patients with severe renal or hepatic impairment, pelvic surgery (except nerve‑sparing prostatectomy) or trauma or radiotherapy and hypoactive sexual desire or penile anatomic deformities have been performed.</p><p>&nbsp;</p><p>Across the pivotal trials, treatment with vardenafil (film-coated tablets) resulted in an improvement of erectile function compared to placebo. In the small number of patients who attempted intercourse up to four to five hours after dosing the success rate for penetration and maintenance of erection was consistently greater than placebo.</p><p>&nbsp;</p><p>In fixed dose studies (film-coated tablets) in a broad population of men with erectile dysfunction, 68% (5&nbsp;mg), 76% (10&nbsp;mg) and 80% (20&nbsp;mg) of patients experienced successful penetrations (SEP&nbsp;2) compared to 49% on placebo over a three month study period. The ability to maintain the erection (SEP&nbsp;3) in this broad ED population was given as 53% (5&nbsp;mg), 63% (10&nbsp;mg) and 65% (20&nbsp;mg) compared to 29% on placebo.</p><p>&nbsp;</p><p>In pooled data from the major efficacy trials, the proportion of patients experiencing successful penetration on vardenafil were as follows: psychogenic erectile dysfunction (77‑87%), mixed erectile dysfunction (69‑83%), organic erectile dysfunction (64‑75%), elderly (52‑75%), ischaemic heart disease (70‑73%), hyperlipidaemia (62‑73%), chronic pulmonary disease (74‑78%), depression (59‑69%), and patients concomitantly treated with antihypertensives (62‑73%).</p><p>&nbsp;</p><p>In a clinical trial in patients with diabetes mellitus, vardenafil significantly improved the erectile function domain score, the ability to obtain and maintain an erection long enough for successful intercourse and penile rigidity compared to placebo at vardenafil doses of 10&nbsp;mg and 20&nbsp;mg. The response rates for the ability to obtain and maintain an erection was 61% and 49% on 10&nbsp;mg and 64% and 54% on 20&nbsp;mg vardenafil compared to 36% and 23% on placebo for patients who completed three months treatment.</p><p>&nbsp;</p><p>In a clinical trial in post-prostatectomy patients, vardenafil significantly improved the erectile function domain score, the ability to obtain and maintain an erection long enough for successful intercourse and penile rigidity compared to placebo at vardenafil doses of 10&nbsp;mg and 20&nbsp;mg. The response rates for the ability to obtain and maintain an erection was 47% and 37% on 10&nbsp;mg and 48% and 34% on 20&nbsp;mg vardenafil compared to 22% and 10% on placebo for patients who completed three months treatment.</p><p>&nbsp;</p><p>In a flexible-dose clinical trial in patients with Spinal Cord Injury, vardenafil significantly improved the erectile function domain score, the ability to obtain and maintain an erection long enough for successful intercourse and penile rigidity compared to placebo. The number of patients who returned to a normal IIEF domain score (<u>&gt;</u>26) were 53% on vardenafil compared to 9% on placebo. The response rates for the ability to obtain and maintain an erection were 76% and 59% on vardenafil compared to 41% and 22% on placebo for patients who completed three months treatment which were clinically and statistically significant (p&lt;0.001).</p><p>&nbsp;</p><p>The safety and efficacy of vardenafil was maintained in long-term studies.</p><p>&nbsp;</p><p><u>Paediatric population</u></p><p>The European Medicines Agency has waived the obligation to submit the results of studies in all subsets of the paediatric population in the treatment of the erectile dysfunction. See section 4.2 for information on paediatric use.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Bioequivalence studies have shown that vardenafil 10&nbsp;mg orodispersible tablet is not bioequivalent to vardenafil 10&nbsp;mg film-coated tablets. Therefore the orodispersible formulation should not be used as an equivalent to vardenafil 10&nbsp;mg film-coated tablets.</p><p><strong>&nbsp;</strong></p><p><u>Absorption</u></p><p>In vardenafil film-coated tablets, vardenafil is rapidly absorbed with maximum observed plasma concentrations reached in some men as early as 15 minutes after oral administration. However, 90% of the time, maximum plasma concentrations are reached within 30 to 120 minutes (median 60 minutes) of oral dosing in the fasted state. The mean absolute oral bioavailability is 15%. After oral dosing of vardenafil AUC and C<sub>max</sub> increase almost dose proportionally over the recommended dose range (5&nbsp;&ndash;&nbsp;20&nbsp;mg).</p><p>&nbsp;</p><p>When vardenafil film-coated tablets are taken with a high fat meal (containing 57% fat), the rate of absorption is reduced, with an increase in the median t<sub>max</sub> of 1 hour and a mean reduction in C<sub>max</sub> of 20%. Vardenafil AUC is not affected. After a meal containing 30% fat, the rate and extent of absorption of vardenafil (t<sub>max</sub>, C<sub>max</sub> and AUC) are unchanged compared to administration under fasting conditions.</p><p><u>&nbsp;</u></p><p>Vardenafil is rapidly absorbed after administration of Levitra 10&nbsp;mg orodispersible tablets without water. The median time to reach C<sub>max</sub> varied between 45 to 90&nbsp;minutes and was similar or slightly delayed (by 8 to 45&nbsp;min) compared to the film-coated tablets. Mean vardenafil AUC was increased by 21 to 29% (middle aged and elderly ED patients) or 44% (young healthy subjects) with 10&nbsp;mg orodispersible tablets compared to film-coated tablets as a result of local oral absorption of a small amount of drug in the oral cavity. There was no consistent difference in mean C<sub>max</sub> between orodispersible tablets and film-coated tablets.</p><p>&nbsp;</p><p>In subjects taking vardenafil 10&nbsp;mg orodispersible tablets with a high fat meal no effect on vardenafil AUC and t<sub>max </sub>was observed, while vardenafil C<sub>max</sub> was reduced by 35% in the fed condition. Based on these results vardenafil 10&nbsp;mg orodispersible tablets can be taken with or without food.</p><p>&nbsp;</p><p>If vardenafil 10&nbsp;mg orodispersible tablets are taken with water, the AUC is reduced by 29%, C<sub>max </sub>remains unchanged and median t<sub>max</sub> is shortened by 60&nbsp;minutes compared to intake without water. Vardenafil 10&nbsp;mg orodispersible tablets must be taken without liquid.</p><p><u>&nbsp;</u></p><p><u>Distribution</u></p><p>The mean steady state volume of distribution for vardenafil is 208&nbsp;l, indicating distribution into the tissues.</p><p>&nbsp;</p><p>Vardenafil and its major circulating metabolite (M1) are highly bound to plasma proteins (approximately 95% for vardenafil or M1). For vardenafil as well as M1, protein binding is independent of total drug concentrations.</p><p>Based on measurements of vardenafil in semen of healthy subjects 90 minutes after dosing, not more than 0.00012% of the administered dose may appear in the semen of patients.</p><p>&nbsp;</p><p><u>Biotransformation</u></p><p>Vardenafil in film-coated tablets is metabolised predominantly by hepatic metabolism via cytochrome P450 (CYP) isoform 3A4 with some contribution from CYP3A5 and CYP2C isoforms.</p><p>&nbsp;</p><p>In humans the one major circulating metabolite (M1) results from desethylation of vardenafil and is subject to further metabolism with a plasma elimination half-life of approximately 4&nbsp;hours. Parts of M1 are in the form of the glucuronide in systemic circulation. Metabolite M1 shows a phosphodiesterase selectivity profile similar to vardenafil and an <em>in vitro</em> potency for phosphodiesterase type 5 of approximately 28% compared to vardenafil, resulting in an efficacy contribution of about 7%.</p><p>&nbsp;</p><p>The mean terminal half-life of vardenafil in patients receiving Levitra 10&nbsp;mg orodispersible tablets ranged between 4&nbsp;&ndash;&nbsp;6 hours. The elimination half-life of the metabolite M1 is between 3&nbsp;to&nbsp;5&nbsp;hours, similar to parent drug.</p><p>&nbsp;</p><p><u>Elimination</u></p><p>The total body clearance of vardenafil is 56&nbsp;l/h with a resultant terminal half-life of approximately 4‑5&nbsp;hours. After oral administration, vardenafil is excreted as metabolites predominantly in the faeces (approximately 91‑95% of the administered dose) and to a lesser extent in the urine (approximately 2‑6% of the administered dose).</p><p>&nbsp;</p><p><u>Pharmacokinetics in special patient groups</u></p><p><em>Elderly</em></p><p>Hepatic clearance of vardenafil in healthy elderly volunteers (65 years and over) was reduced as compared to healthy younger volunteers (18&nbsp;‑&nbsp;45 years). On average elderly males taking vardenafil film-coated tablets had a 52% higher AUC, and a 34% higher C<sub>max</sub> than younger males (see section 4.2).</p><p>&nbsp;</p><p>Vardenafil AUC and C<sub>max</sub> in elderly patients (65 years or over) taking vardenafil orodispersible tablets were increased by 31 to 39% and 16 to 21%, respectively, in comparison to patients aged 45 years and below. Vardenafil was not found to accumulate in the plasma in patients aged 45 years and below or 65 years or over following once-daily dosing of vardenafil 10&nbsp;mg orodispersible tablets over ten days.</p><p>&nbsp;</p><p><em>Renal impairment</em></p><p>In volunteers with mild to moderate renal impairment (creatinine clearance 30&nbsp;&ndash;&nbsp;80&nbsp;ml/min), the pharmacokinetics of vardenafil were similar to that of a normal renal function control group. In volunteers with severe renal impairment (creatinine clearance &lt;30&nbsp;ml/min) the mean AUC was increased by 21% and the mean C<sub>max</sub> decreased by 23%, compared to volunteers with no renal impairment. No statistically significant correlation was observed between creatinine clearance and vardenafil exposure (AUC and C<sub>max</sub>) (see section 4.2). Vardenafil pharmacokinetics has not been studied in patients requiring dialysis (see section 4.3).</p><p><strong>&nbsp;</strong></p><p><em>Hepatic impairment</em></p><p>In patients with mild to moderate hepatic impairment (Child‑Pugh A and B), the clearance of vardenafil was reduced in proportion to the degree of hepatic impairment. In patients with mild hepatic impairment (Child‑Pugh A), the mean AUC and C<sub>max</sub> increased 17% and 22% respectively, compared to healthy control subjects. In patients with moderate impairment (Child‑Pugh B), the mean AUC and C<sub>max</sub> increased by 160% and 133% respectively, compared to healthy control subjects (see section 4.2). The pharmacokinetics of vardenafil in patients with severely impaired hepatic function (Child‑Pugh C) has not been studied (see section 4.3).</p><p>&nbsp;</p><p><u>Additional information</u></p><p>In vitro data suggest that effects of vardenafil on P-glycoprotein substrates more sensitive than digoxin cannot be excluded. Dabigatran etexilate is an example for highly sensitive intestinal P-glycoprotein substrates.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Non-clinical data reveal no special hazard for humans based on conventional studies of safety pharmacology, repeated dose toxicity, genotoxicity, carcinogenic potential, toxicity to reproduction.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p style="margin-right:-.1pt"><u>Tablet core:</u></p><p style="margin-right:-.1pt">Crospovidone</p><p style="margin-right:-.1pt">Magnesium stearate</p><p style="margin-right:-.1pt">Microcrystalline cellulose</p><p style="margin-right:-.1pt">Silica, colloidal anhydrous</p><p style="margin-right:-.1pt">&nbsp;</p><p><u>Film coat:</u></p><p>Macrogol 400</p><p>Hypromellose</p><p>Titanium dioxide (E171)</p><p>Ferric oxide yellow (E172)</p><p>Ferric oxide red (E172)</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Not applicable.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                3 years
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Do not store above 25&deg;C.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>PP/Aluminium foil blisters in cartons of 2, 4, 8, 12 and 20 tablets.</p><p>&nbsp;</p><p>Not all pack sizes may be marketed.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>No special requirements for disposal.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Bayer AG
51373 Leverkusen
Germany

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                03/2020
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>